Dai un'occhiata al Libro degli ospiti
Pagina 1 - 30 di 15031 results
Nome Commento
home colon cleanse drink maid service jobs in las vegas

Posted at martedì, 23 settembre 2014 15:32 Visit posters website
best cleaner for black car interior hourly maid service in dubai office cleaning jobs in san antonio tx
 
Katie Newman

Posted at lunedì, 22 settembre 2014 17:09 Visit posters website
Vaporin, Inc. Continues Expansion of The Vape Store Retail Locations

MIAMI, FL--(Marketwired - Sep 22, 2014) - Vaporin, Inc. (OTCQB: VAPOD), a distributor and marketer of vaporizers and e-liquids products, today announced they have signed a lease for the opening of another Vape Store. Located in North Fort Myers, Florida, the new store is positioned in a highly visible and heavily trafficked area. The Company is using cash flow from existing Vape Store locations to fund the development of the new store; no additional investment is needed.

Retail store sales continue to be one of the fastest growing segments of the vapor market. In fact, the number of vape stores have tripled over the last year. According to a recent report issued by Wells Fargo, the e-cigarette market has decreased $400 million from $1.4 billion to $1 billion while vaporizers, tanks, and mods have increased $400 million from $1.1 billion to $1.5 billion. The retail vape store segment alone has also grown to be a $1 billion market.

The Company recognizes this trend and is focused on the expansion of The Vape Store retail locations. Vaporin, Inc. has plans to aggressively accelerate the growth of their retail store model with continued acquisitions of existing stores as well as opening new store locations. Currently, the Company forecasts approximately $650,000 in annual revenue per vape store.

CEO Scott Frohman said, "The opening of another Vape Store is part of our strategy to continuously build out our multi-pronged revenue model. We are very pleased with the production from our current Vape Stores as the cash flow generated has enabled us to build out this new location without taking on any additional investment. This allows us to increase shareholder equity as we continue to execute on our business plan. We are very confident in our ability to quickly turn retail stores cash flow positive and will continue to move aggressively towards expanding our retail store, online sales and distribution market shares."

About Vaporin, Inc.
Vaporin is a distributor and marketer of vaporizers and e-liquids products. The Company focuses on a multi-pronged revenue model comprised of convenience store sales, online retail continuity programs, vending machines, and the acquisition and opening of brick and mortar retail stores. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin is offered in a variety of disposable and rechargeable starter kits and flavors. The unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements including statements regarding future Vape Store acquisitions and opening new Vape Stores. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the results of our marketing efforts including our online initiative, competition from other e-cig. companies and the major tobacco companies, our ability to efficiently and productively integrate our recent acquisition, our future stock price and cash resources, and new regulations which affect the distribution of these products. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

All of the securities were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 (the "Act") and Rule 506 promulgated thereunder. These securities may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements under the Act. The investors are accredited investors and there was no general solicitation.
Contact:


Company
Vaporin, Inc.
Scott Frohman
Chief Executive Officer
305.842.2813
Email Contact

Investor Relations
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 x201
or
(212) 398-3486
Email Contact
 
Katie Newman

Posted at lunedì, 22 settembre 2014 17:06 Visit posters website
Vaporin, Inc. Continues Expansion of The Vape Store Retail Locations

MIAMI, FL--(Marketwired - Sep 22, 2014) - Vaporin, Inc. (OTCQB: VAPOD), a distributor and marketer of vaporizers and e-liquids products, today announced they have signed a lease for the opening of another Vape Store. Located in North Fort Myers, Florida, the new store is positioned in a highly visible and heavily trafficked area. The Company is using cash flow from existing Vape Store locations to fund the development of the new store; no additional investment is needed.

Retail store sales continue to be one of the fastest growing segments of the vapor market. In fact, the number of vape stores have tripled over the last year. According to a recent report issued by Wells Fargo, the e-cigarette market has decreased $400 million from $1.4 billion to $1 billion while vaporizers, tanks, and mods have increased $400 million from $1.1 billion to $1.5 billion. The retail vape store segment alone has also grown to be a $1 billion market.

The Company recognizes this trend and is focused on the expansion of The Vape Store retail locations. Vaporin, Inc. has plans to aggressively accelerate the growth of their retail store model with continued acquisitions of existing stores as well as opening new store locations. Currently, the Company forecasts approximately $650,000 in annual revenue per vape store.

CEO Scott Frohman said, "The opening of another Vape Store is part of our strategy to continuously build out our multi-pronged revenue model. We are very pleased with the production from our current Vape Stores as the cash flow generated has enabled us to build out this new location without taking on any additional investment. This allows us to increase shareholder equity as we continue to execute on our business plan. We are very confident in our ability to quickly turn retail stores cash flow positive and will continue to move aggressively towards expanding our retail store, online sales and distribution market shares."

About Vaporin, Inc.
Vaporin is a distributor and marketer of vaporizers and e-liquids products. The Company focuses on a multi-pronged revenue model comprised of convenience store sales, online retail continuity programs, vending machines, and the acquisition and opening of brick and mortar retail stores. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin is offered in a variety of disposable and rechargeable starter kits and flavors. The unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements including statements regarding future Vape Store acquisitions and opening new Vape Stores. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the results of our marketing efforts including our online initiative, competition from other e-cig. companies and the major tobacco companies, our ability to efficiently and productively integrate our recent acquisition, our future stock price and cash resources, and new regulations which affect the distribution of these products. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

All of the securities were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 (the "Act") and Rule 506 promulgated thereunder. These securities may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements under the Act. The investors are accredited investors and there was no general solicitation.
Contact:


Company
Vaporin, Inc.
Scott Frohman
Chief Executive Officer
305.842.2813
Email Contact

Investor Relations
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 x201
or
(212) 398-3486
Email Contact
 
Katie Newman

Posted at lunedì, 22 settembre 2014 16:32 Visit posters website
Why Vaporin, Inc Should be Trading at $15

After taking a long look at the landscape of the vaporizer industry the obvious trend is two-fold with the decline in e-cig popularity coupled with the increasing opportunity for companies producing vaporizers and e-liquid products gaining majority within the market. The tides have changed in a drastic way and unfortunately it's not to the benefit of this latest electronic cigarette M&A trend coming from Big Tobacco.

The commotion began earlier this summer when rumors were spreading that Lorillard (LO) maker of the blu e-cig was a possible buyout candidate from US tobacco company, Reynold’s America (RAI). Well, the rumors were true and in fact Reynold’s made a $27.4Billion offer where shares of Lorillard skyrocketed. Analysts at Wells Fargo (WFC) believe e-cigarette sales will surpass traditional tobacco where the industry is expected to hit $10 billion by 2017. With triple-digit growth rates still in its future, and tobacco sales declining, it’s assumed that the two will cross-over. Despite the previous growth of blu brand, its market share has fallen as a result of more competition within the space.


Both Reynolds and Altria (MO) rolled out their own e-cig brands with the addition of Vuse and Mark Ten, but this may not be the only reason for the rapid decline. As noted in a more recent Wells Fargo study, the overall appeal of e-cigarettes has diminished and smokers are looking for an alternative product that will offer both customizability and more choices. Analysts from Wells found that e-cig convenience store sales declined by 5.3% in the period ending 8/30/14, “Though category $ sales remain negative, the decline continued to moderate this period; we believe improved sequential category results since July have been underpinned by the ongoing national rollouts of MarkTen and Vuse…Further, we believe the sales decline is more reflective of volume moving to vapors-tanks- mods (VTMs) which tend to be sold in non-tracked channels (especially vape shops) as Nielsen e-cig data is not a proxy for the vapor category as a whole.”

Many retailers have expressed that consumers have tried e-cigs and are either not content with the product or simply shifted to personal vaporizer products. Convenience stores for example, rank as one of the largest marketplaces for e-cig sales ($530M) but vaporizers have quickly begun taking up more shelf space and spots for point of sale advertising. Bonnie Herzog of Wells Fargo thinks that the first quarter of 2014 is where the industry started to really see the vapor trend gain a foothold and drive the combustible cig and e-cig decline rate at an accelerated pace.

"Bottom line, retailers are starting to either discontinue or take shelf space away from disposable e-cigs to make room for personal vaporizers given their attractive growth & margins."

But here’s the thing, take a look at the vaporizer market and you’ll quickly begin to see how fragmented it actually is. You have independently owned single store locations and head shops yet on the other end you have several public companies that have started to build their brands around the new vapor trend; still there has not been a clear market leader like there was with the e-cigarette industry. With Big Tobacco seeming to be looking in the wrong direction for the “alternative smoking” industry, the top spot is up for grabs and we have been following a company that may be quickly growing to take that spot.

In looking at the current layout of the market today, you’ll certainly find companies out there that boast lofty numbers and inflated marketing programs that include heavy celebrity endorsements and over exaggerated development. Nonetheless, when making a strong investment decision, knowing what else is out there is paramount. For instance, Electronic Cigarettes International (ECIG) recently announced operating results for the second quarter and six months ending June 30 of this year. Net sales increased to $15.4 million for the six months ended June 30, 2014, an increase of 875% versus prior year with nearly 2/3 of this revenue coming in during the first quarter of 2014. The company even brought on actress and model Mischa Barton as the ECIG’s face to its VAPESTICK® Style Icon campaign. But despite these developments, the company reported a net loss that was nearly 5 and a-half times larger than its total revs. The company also trades at roughly 26 times revenue and has a good operating margin of 53% for the 6 months ending June 30.

Even with these results, the stock price has taken a plunge suffering a pull-back of more than $2 since July. It’s evident that the company will really need to ramp up its efforts during the second half of the year to turn around its stock price. More importantly ECIG still seems to have a heavy focus on the electronic cigarette market and as noted by several analysts, this will most likely face heavy consolidation as vaporizers and e-liquids take on a larger appeal.

mCig, Inc. (MCIG) has also begun an aggressive branding strategy but like ECIG, still continues to focus more on the e-cigarette style products. In its most recent press the company reported favorable progress numbers including a 1500% increase in revenues from an abysmal $12.5k last year to a second quarter “expected” number of $196k. Gross margin was also healthy at just over 50% which does not reflect the “recent price increase of both the mCig® and VitaCig® which the company believes will contribute to an increase in Gross Profit Margin in subsequent quarters.” As has been the case with the previously mentioned company, mCig has its “stars aligned” through a master royalty and consulting agreement with hip-hop ‘mogul’ Rick Ross. Even though the company has seen a dramatic pullback in price, it appears that it is still moving forward with the planned S-1 filing for a spinoff, IPO, and dividend of VitaCig, Inc. So it will be interesting to see what kind of operational strategy will take shape as far as the stance on vaporizers once VitaCig becomes its own entity.
But once again, we are left with the lack of a true industry leader. Both of these previously mentioned companies who’ve employed heavy R&D plus the addition of celebrities to support the brands have seen a dramatic drop in stock price. Vaporin, Inc. (VAPO) is an interesting company that has just recently performed a 1-for-50-reverse. The Company is a distributor and marketer of vaporizers and e-liquids products. VAPO has also just released its second quarter earnings as well as its results for the first 6 months of 2014.

Vaporin has earned about $600,000 so far this year with a gross profit margin of 41%. In addition, VAPO has obtained roughly $4.3million through equity purchases, which has helped the company increase its inventory and proceed with proper distribution to support the sales growth, and new product development of its vaporizer & e-liquid products. Also note that these raises were done where the effective purchase price was at or above $5 per share which currently would protect the market from any heavy dilution assuming the funding parties would want to at least break even.
Moreover, the company recently announced that it is moving forward with its "fourth revenue driver" through rolling up vaporizer businesses within this highly fragmented industry. On September 3 the company announced the closing of its acquisition of The Vape Store (** and also just signed a lease to open a 5th vape shop in Florida. With previously announced annualized revenue of $2.6million from the first four stores the company acquired, this new store could bump that number to somewhere in the ballpark of $3.25million if the new store has the same kind of revenue performance as the other 4.

In addition to this, the post reverse price puts this stock at a level that should attract a much more sophisticated investor audience as compared to when it was trading at less than $0.10. In fact the latest feature on Biz Journals . com shows that Billionaire Dr. Phillip Frost (who made his fortune treating diseases) is now an investor in this vaporizer and e-liquids company. Frost owns actually 10.8 percent of Vaporin, which operates out of the same building as his company Opko Health, according to SEC documents filed in August.

Instead of celebrity spokes people or social media campaigning, Vaporin is using the same strategy that blu used during its early development not only to gain an early market share in the vape space but also to establish itself as a potential leader in the vaporizer & e-liquids industry. In addition to these revenue channels, the company has diversified through both an online sales approach & continuity program as well as its nationwide convenience store roll-out. And if this wasn’t enough, Vaporin has taken a seat in the cannabis market through a product distribution agreement with Terra Tech Inc. (TRTC).

If you look at all of these companies including Lorillard, Altria, Reynolds, mCig, and Electronic Cigarettes International they are all going against what top analysts like Wells Fargo are finding, which is to say that e-cigs are drastically declining in popularity and are now having to even adopt more of a “low price” strategy just to compete. The facts remain that of the entire $2.5billion vapor market, vaporizers, tanks and mods have surpassed the market share for E-Cigs by half a billion dollars with the majority of sales coming from brick and mortar retail.


To this end, Vaporin has been the single stand-out that’s not only continuing to post quarter over quarter revenue growth but is also working to expand with the industry itself. This past quarter the company reported revenues of $419k showing quarter over quarter growth of 130%. But say the company didn’t see growth at all over the next 2 quarters and simply maintained operations while taking in revenue from the vape stores. Over the next four quarters that would put total revenue run rate somewhere around the $5million (*assuming an additional $3.25m from vape stores over the next four quarters). ECIG currently trades at a revenue multiple of about 26x and MCIG as of the closing of their fourth quarter ending in April is right around 300x but say that Vaporin simply settles the next four months out with no growth, maintains its current relationships, and takes in revenue from the vape stores; even at a conservative 10X multiple, not only would the market value be upwards of $50M but with a current OS of about 3.5 million shares, the market price for VAPO could be sitting somewhere around the $14-$18 range. For these reasons and based on the overall amount of developments that the company has undertaken, Vaporin, Inc. remains the stand-out for a viable market leading company in this burgeoning vaporizer and e-liquids market.

*Note: Additional $1.625M from quarterly revenues based on an annualized $3.25m plus three quarters of company revs being $419,000 and first quarter revenues of $183,000

Pursuant to an agreement between us and a Vaporin, Inc., we were hired for a 14 day period period beginning on 8/10/14 and ending on9/24/14 to publicly disseminate information about Vaporin, Inc. , including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for or were paid "ZERO" shares of unrestricted or restricted common shares. We own zero shares of Vaporin, Inc. , which we purchased in the open market. We plan to sell the "ZERO" shares of Vaporin, Inc. that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Vaporin, Inc. , in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.




Vaporin Inc. (OTCBB:VAPOD)
Historical Stock Chart
1 Year : From Sep 2013 to Sep 2014
Vaporin Inc. (OTCBB:VAPOD)
Intraday Stock Chart
Today : Monday 22 September 2014


 
Katie Newman

Posted at lunedì, 22 settembre 2014 16:28 Visit posters website
Why Vaporin, Inc Should be Trading at $15

After taking a long look at the landscape of the vaporizer industry the obvious trend is two-fold with the decline in e-cig popularity coupled with the increasing opportunity for companies producing vaporizers and e-liquid products gaining majority within the market. The tides have changed in a drastic way and unfortunately it's not to the benefit of this latest electronic cigarette M&A trend coming from Big Tobacco.

The commotion began earlier this summer when rumors were spreading that Lorillard (LO) maker of the blu e-cig was a possible buyout candidate from US tobacco company, Reynold’s America (RAI). Well, the rumors were true and in fact Reynold’s made a $27.4Billion offer where shares of Lorillard skyrocketed. Analysts at Wells Fargo (WFC) believe e-cigarette sales will surpass traditional tobacco where the industry is expected to hit $10 billion by 2017. With triple-digit growth rates still in its future, and tobacco sales declining, it’s assumed that the two will cross-over. Despite the previous growth of blu brand, its market share has fallen as a result of more competition within the space.


Both Reynolds and Altria (MO) rolled out their own e-cig brands with the addition of Vuse and Mark Ten, but this may not be the only reason for the rapid decline. As noted in a more recent Wells Fargo study, the overall appeal of e-cigarettes has diminished and smokers are looking for an alternative product that will offer both customizability and more choices. Analysts from Wells found that e-cig convenience store sales declined by 5.3% in the period ending 8/30/14, “Though category $ sales remain negative, the decline continued to moderate this period; we believe improved sequential category results since July have been underpinned by the ongoing national rollouts of MarkTen and Vuse…Further, we believe the sales decline is more reflective of volume moving to vapors-tanks- mods (VTMs) which tend to be sold in non-tracked channels (especially vape shops) as Nielsen e-cig data is not a proxy for the vapor category as a whole.”

Many retailers have expressed that consumers have tried e-cigs and are either not content with the product or simply shifted to personal vaporizer products. Convenience stores for example, rank as one of the largest marketplaces for e-cig sales ($530M) but vaporizers have quickly begun taking up more shelf space and spots for point of sale advertising. Bonnie Herzog of Wells Fargo thinks that the first quarter of 2014 is where the industry started to really see the vapor trend gain a foothold and drive the combustible cig and e-cig decline rate at an accelerated pace.

"Bottom line, retailers are starting to either discontinue or take shelf space away from disposable e-cigs to make room for personal vaporizers given their attractive growth & margins."

But here’s the thing, take a look at the vaporizer market and you’ll quickly begin to see how fragmented it actually is. You have independently owned single store locations and head shops yet on the other end you have several public companies that have started to build their brands around the new vapor trend; still there has not been a clear market leader like there was with the e-cigarette industry. With Big Tobacco seeming to be looking in the wrong direction for the “alternative smoking” industry, the top spot is up for grabs and we have been following a company that may be quickly growing to take that spot.

In looking at the current layout of the market today, you’ll certainly find companies out there that boast lofty numbers and inflated marketing programs that include heavy celebrity endorsements and over exaggerated development. Nonetheless, when making a strong investment decision, knowing what else is out there is paramount. For instance, Electronic Cigarettes International (ECIG) recently announced operating results for the second quarter and six months ending June 30 of this year. Net sales increased to $15.4 million for the six months ended June 30, 2014, an increase of 875% versus prior year with nearly 2/3 of this revenue coming in during the first quarter of 2014. The company even brought on actress and model Mischa Barton as the ECIG’s face to its VAPESTICK® Style Icon campaign. But despite these developments, the company reported a net loss that was nearly 5 and a-half times larger than its total revs. The company also trades at roughly 26 times revenue and has a good operating margin of 53% for the 6 months ending June 30.

Even with these results, the stock price has taken a plunge suffering a pull-back of more than $2 since July. It’s evident that the company will really need to ramp up its efforts during the second half of the year to turn around its stock price. More importantly ECIG still seems to have a heavy focus on the electronic cigarette market and as noted by several analysts, this will most likely face heavy consolidation as vaporizers and e-liquids take on a larger appeal.

mCig, Inc. (MCIG) has also begun an aggressive branding strategy but like ECIG, still continues to focus more on the e-cigarette style products. In its most recent press the company reported favorable progress numbers including a 1500% increase in revenues from an abysmal $12.5k last year to a second quarter “expected” number of $196k. Gross margin was also healthy at just over 50% which does not reflect the “recent price increase of both the mCig® and VitaCig® which the company believes will contribute to an increase in Gross Profit Margin in subsequent quarters.” As has been the case with the previously mentioned company, mCig has its “stars aligned” through a master royalty and consulting agreement with hip-hop ‘mogul’ Rick Ross. Even though the company has seen a dramatic pullback in price, it appears that it is still moving forward with the planned S-1 filing for a spinoff, IPO, and dividend of VitaCig, Inc. So it will be interesting to see what kind of operational strategy will take shape as far as the stance on vaporizers once VitaCig becomes its own entity.
But once again, we are left with the lack of a true industry leader. Both of these previously mentioned companies who’ve employed heavy R&D plus the addition of celebrities to support the brands have seen a dramatic drop in stock price. Vaporin, Inc. (VAPO) is an interesting company that has just recently performed a 1-for-50-reverse. The Company is a distributor and marketer of vaporizers and e-liquids products. VAPO has also just released its second quarter earnings as well as its results for the first 6 months of 2014.

Vaporin has earned about $600,000 so far this year with a gross profit margin of 41%. In addition, VAPO has obtained roughly $4.3million through equity purchases, which has helped the company increase its inventory and proceed with proper distribution to support the sales growth, and new product development of its vaporizer & e-liquid products. Also note that these raises were done where the effective purchase price was at or above $5 per share which currently would protect the market from any heavy dilution assuming the funding parties would want to at least break even.
Moreover, the company recently announced that it is moving forward with its "fourth revenue driver" through rolling up vaporizer businesses within this highly fragmented industry. On September 3 the company announced the closing of its acquisition of The Vape Store (** and also just signed a lease to open a 5th vape shop in Florida. With previously announced annualized revenue of $2.6million from the first four stores the company acquired, this new store could bump that number to somewhere in the ballpark of $3.25million if the new store has the same kind of revenue performance as the other 4.

In addition to this, the post reverse price puts this stock at a level that should attract a much more sophisticated investor audience as compared to when it was trading at less than $0.10. In fact the latest feature on Biz Journals . com shows that Billionaire Dr. Phillip Frost (who made his fortune treating diseases) is now an investor in this vaporizer and e-liquids company. Frost owns actually 10.8 percent of Vaporin, which operates out of the same building as his company Opko Health, according to SEC documents filed in August.

Instead of celebrity spokes people or social media campaigning, Vaporin is using the same strategy that blu used during its early development not only to gain an early market share in the vape space but also to establish itself as a potential leader in the vaporizer & e-liquids industry. In addition to these revenue channels, the company has diversified through both an online sales approach & continuity program as well as its nationwide convenience store roll-out. And if this wasn’t enough, Vaporin has taken a seat in the cannabis market through a product distribution agreement with Terra Tech Inc. (TRTC).

If you look at all of these companies including Lorillard, Altria, Reynolds, mCig, and Electronic Cigarettes International they are all going against what top analysts like Wells Fargo are finding, which is to say that e-cigs are drastically declining in popularity and are now having to even adopt more of a “low price” strategy just to compete. The facts remain that of the entire $2.5billion vapor market, vaporizers, tanks and mods have surpassed the market share for E-Cigs by half a billion dollars with the majority of sales coming from brick and mortar retail.


To this end, Vaporin has been the single stand-out that’s not only continuing to post quarter over quarter revenue growth but is also working to expand with the industry itself. This past quarter the company reported revenues of $419k showing quarter over quarter growth of 130%. But say the company didn’t see growth at all over the next 2 quarters and simply maintained operations while taking in revenue from the vape stores. Over the next four quarters that would put total revenue run rate somewhere around the $5million (*assuming an additional $3.25m from vape stores over the next four quarters). ECIG currently trades at a revenue multiple of about 26x and MCIG as of the closing of their fourth quarter ending in April is right around 300x but say that Vaporin simply settles the next four months out with no growth, maintains its current relationships, and takes in revenue from the vape stores; even at a conservative 10X multiple, not only would the market value be upwards of $50M but with a current OS of about 3.5 million shares, the market price for VAPO could be sitting somewhere around the $14-$18 range. For these reasons and based on the overall amount of developments that the company has undertaken, Vaporin, Inc. remains the stand-out for a viable market leading company in this burgeoning vaporizer and e-liquids market.

*Note: Additional $1.625M from quarterly revenues based on an annualized $3.25m plus three quarters of company revs being $419,000 and first quarter revenues of $183,000

Pursuant to an agreement between us and a Vaporin, Inc., we were hired for a 14 day period period beginning on 8/10/14 and ending on9/24/14 to publicly disseminate information about Vaporin, Inc. , including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for or were paid "ZERO" shares of unrestricted or restricted common shares. We own zero shares of Vaporin, Inc. , which we purchased in the open market. We plan to sell the "ZERO" shares of Vaporin, Inc. that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Vaporin, Inc. , in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.




Vaporin Inc. (OTCBB:VAPOD)
Historical Stock Chart
1 Year : From Sep 2013 to Sep 2014
Vaporin Inc. (OTCBB:VAPOD)
Intraday Stock Chart
Today : Monday 22 September 2014


 
Katie Newman

Posted at lunedì, 22 settembre 2014 16:02 Visit posters website
Progressive Green Solutions, Inc. (symbol: PGSC)
We are issuing an immediate potential breakout alert for Progressive Green Solutions, Inc. (PGSC). This company has goals of becoming a leader in what Barry Judge, CMO of Best Buy, is calling a $15Bil industry in the U.S. alone. The market potential is enormous and the setup primed. (PGSC) appears to have developed a Bull Flag pattern that happens to be our favorite setup. The closest resistance level appears to be well above the $3.00 mark. This means that it is very possible we could see a breakout post gains well north of 50% should (PGSC) start to build momentum in our favor. With such a huge market potential and seemingly bullish chart setup, we urge you to begin researching (PGSC) right away. This is a time sensitive alert that could ignite very quickly so don’t waste another minute. Get moving now because not many people are aware this opportunity even exists!
This undiscovered industry is known as reverse logistics or secondary market for refurbished goods. Companies like GE, Amazon, and eBay are also making strategic moves to capitalize on this “secret” market opportunity that (PGSC) is already thriving in.
About Progressive Green Solutions, Inc. (PGSC).
Progressive Green Solutions is a full service returns management solution provider that specializes in reverse logistics, remanufacturing, repair and recovery, engineering/quality assurance, warehousing and fulfillment, secondary market sales and e-commerce for retailers and manufacturers of major appliances, small appliances, floor care products, air-conditioning/filtration products, small electronics, power tools and outdoor power equipment products. Through their unique combinations of services and logistics, (PGSC) is able to provide its clients with a one stop turnkey solution to manage, ship and process its clients returned merchandise.
(PGSC) Investor Highlights.
1. Undiscovered market opportunity.
2. Best Buy CMO says market value is $15Bil in the U.S. alone.
3. Potential Bull Flag chart setup.
4. Fortune 500 companies like GE and Amazon also see the profit potential within the industry.
5. Value of U.S. remanufactured goods grew by 15% to $43Bil according to the U.S. International Trade Commission in 2011.
6. The average consumer saves about 30% on a refurbished item.
7. This secondary market represents about 3% of the entire U.S. GDP.
(PGSC) Summary.
PGSC is operating in a unique yet enormous market that not many people are aware even exists. This could give investors an opportunity to get involved in an industry with tremendous potential before the rest of Main Street. With what appears to be a Bull Flag chart setup, PGSC could be setting up for a momentum building breakout. As more Fortune 500 companies enter the secondary or reverse logistics space, more and more investors are sure to become aware of the market opportunity present and will look for the best value propositions in the industry. Be sure to begin researching Progressive Green Solutions before that happens. This could be a great opportunity to capitalize on a huge yet undiscovered market.
________________________________________
Start Your Research on (symbol: PGSC) Right Now. Remember the VERY BEST Chance for Gains are @ the Opening 9:30am est Bell This (Mon. 9/22) Morning.
(If You Choose...)
________________________________________________________________________________
Pursuant to an agreement between us and MARKETMOBILETEXT INC and PROGRESSIVE GREEN SOLUTIONS INC we were hired for a 30 day period period beginning on 9/21/14 and ending on 10/21/14 to publicly disseminate information about Progressive Green Solutions, Inc. , including on the Website and other media including Facebook and Twitter. We are being paid $250,000 (CASH) for or were paid "ZERO" shares of unrestricted or restricted common shares. We own zero shares of Progressive Green Solutions, Inc. , which we purchased in the open market. We plan to sell the "ZERO" shares of Progressive Green Solutions, Inc. that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Progressive Green Solutions, Inc. , in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
 
home cleaning service new york city i need a maid to clean my house

Posted at sabato, 20 settembre 2014 19:51 Visit posters website
home kitchen cleaning schedule maid service price per hour
 
Katie Newman

Posted at venerdì, 19 settembre 2014 16:44 Visit posters website
Wells Fargo Analysts Think Investors Should Get With Vapor

New Alert: Vaporin, Inc. (VAPOD)

Capitalize on an industry that Wells Fargo analysts are drooling over with Vaporin, Inc. (VAPOD). Bonnie Herzog, Senior Beverage and Tobacco Analyst at Wells Fargo, has been quite vocal with her bullish stance on the vapor industry as it relates to a declining e-cigarette market. In a recent report, the e-cigarette market dropped from $1.4Bil to $1Bil while vaporizer, tanks, and mods increased from $1.1Bil to $1.5Bil. In addition, the vapor store model has, too, recently become a $1Bil industry. And VAPOD is taking advantage of it all. This vaporizer/e-liquid company is making strategic moves to gain large chunks of market share in this exciting, hyper-growth industry. And with growth statistics like the ones being published by Wells Fargo, you certainly need to take a closer look.

Vaporin, Inc. is blowing out its competition as several companies race to be at the front of the line of this booming industry. Similar to Blu and Logics being acquired for huge valuations when e-cigarettes first became popular, vapor companies are moving quickly to swallow up market share every chance they get. But none seem to be doing it faster and more efficiently than Vaporin, Inc. And here’s why.

Investor Highlights

- $602,000 in revenue in just their first 2 quarters of operation.

- Acquired 4 vape stores adding $2.6Mil in revenue to the books.

- Billionaire investor Dr. Phil Frost has acquired a 10.8% stake in Vaporin, Inc.

- Has plans to open own chain of vape stores.

- Continuing to work towards further vape store acquisitions to increase revenue.

- Successful online continuity program increases both customer satisfaction and reoccurring revenue.

- Distribution agreement with the largest convenience store distributor on the East Coast.

- More than doubled the number of states that their product is distributed to from Q1 to Q2.

The Vapor Industry is Exploding

You would have a hard time finding an industry currently experiencing similar growth rates as seen in the vapor industry. Bonnie Herzog said, “Vapor consumption is believed to surpass combustible cigarettes in the next decade.” Could you imagine investing in one of today’s big tobacco companies during their first year of operation many years ago? The gains on your investment would be astronomical. Well, we believe there to be similar opportunities in the vapor industry today.

Vaporin, Inc. (VAPOD), in less than one year of operation, has already surpassed several competitors’ total sales figures. This company is quickly catapulting itself to the top of the industry and it’s about time you took notice.

The Vaporin Advantage

Vaporin, Inc. has established and completed a four-pronged revenue strategy that includes online retail distribution, strong convenience store presence, vending machines, and vape stores. This company is hitting this industry from all angles and we believe this is the best way to gain the largest market share the quickest and is why we are labeling VAPOD as our #1 vapor play.

We believe VAPOD could be to the vapor industry what Blu and Logics were to the e-cigarette market. Blu and Logics were first to capture a large market share of the e-cigarette industry and were rewarded with hefty buyouts later down the road. It is very possible that a similar fate is in store for Vaproin, Inc. And if they continue to increase revenue by 131% quarter over quarter and continue acquiring high revenue producing vape stores, it could happen much sooner than later.

Large tobacco companies aren’t blind. They see the growth and feel the decline in sales. In fact, Blu’s sales are down about 35%. Meanwhile, the vaporizer market has grown from $1.1Bil to $1.5Bil. It’s no secret the two industries are heading in complete opposite directions. Big tobacco did it before when Blu and Logics were acquired and we expect them to make the exact same move when it comes to the vapor industry. Finding the right ground-floor opportunity in a vapor industry leader now could pay monster dividends down the road. This is why we want you to begin researching Vaproin, Inc. (VAPOD) right now.

Read The Disclaimer Right Here & Right Now: **
#pennystock #pennyStocks #daytrading #daytrade #daytrader
 
Katie Newman

Posted at venerdì, 19 settembre 2014 16:39 Visit posters website
Wells Fargo Analysts Think Investors Should Get With Vapor

New Alert: Vaporin, Inc. (VAPOD)

Capitalize on an industry that Wells Fargo analysts are drooling over with Vaporin, Inc. (VAPOD). Bonnie Herzog, Senior Beverage and Tobacco Analyst at Wells Fargo, has been quite vocal with her bullish stance on the vapor industry as it relates to a declining e-cigarette market. In a recent report, the e-cigarette market dropped from $1.4Bil to $1Bil while vaporizer, tanks, and mods increased from $1.1Bil to $1.5Bil. In addition, the vapor store model has, too, recently become a $1Bil industry. And VAPOD is taking advantage of it all. This vaporizer/e-liquid company is making strategic moves to gain large chunks of market share in this exciting, hyper-growth industry. And with growth statistics like the ones being published by Wells Fargo, you certainly need to take a closer look.

Vaporin, Inc. is blowing out its competition as several companies race to be at the front of the line of this booming industry. Similar to Blu and Logics being acquired for huge valuations when e-cigarettes first became popular, vapor companies are moving quickly to swallow up market share every chance they get. But none seem to be doing it faster and more efficiently than Vaporin, Inc. And here’s why.

Investor Highlights

- $602,000 in revenue in just their first 2 quarters of operation.

- Acquired 4 vape stores adding $2.6Mil in revenue to the books.

- Billionaire investor Dr. Phil Frost has acquired a 10.8% stake in Vaporin, Inc.

- Has plans to open own chain of vape stores.

- Continuing to work towards further vape store acquisitions to increase revenue.

- Successful online continuity program increases both customer satisfaction and reoccurring revenue.

- Distribution agreement with the largest convenience store distributor on the East Coast.

- More than doubled the number of states that their product is distributed to from Q1 to Q2.

The Vapor Industry is Exploding

You would have a hard time finding an industry currently experiencing similar growth rates as seen in the vapor industry. Bonnie Herzog said, “Vapor consumption is believed to surpass combustible cigarettes in the next decade.” Could you imagine investing in one of today’s big tobacco companies during their first year of operation many years ago? The gains on your investment would be astronomical. Well, we believe there to be similar opportunities in the vapor industry today.

Vaporin, Inc. (VAPOD), in less than one year of operation, has already surpassed several competitors’ total sales figures. This company is quickly catapulting itself to the top of the industry and it’s about time you took notice.

The Vaporin Advantage

Vaporin, Inc. has established and completed a four-pronged revenue strategy that includes online retail distribution, strong convenience store presence, vending machines, and vape stores. This company is hitting this industry from all angles and we believe this is the best way to gain the largest market share the quickest and is why we are labeling VAPOD as our #1 vapor play.

We believe VAPOD could be to the vapor industry what Blu and Logics were to the e-cigarette market. Blu and Logics were first to capture a large market share of the e-cigarette industry and were rewarded with hefty buyouts later down the road. It is very possible that a similar fate is in store for Vaproin, Inc. And if they continue to increase revenue by 131% quarter over quarter and continue acquiring high revenue producing vape stores, it could happen much sooner than later.

Large tobacco companies aren’t blind. They see the growth and feel the decline in sales. In fact, Blu’s sales are down about 35%. Meanwhile, the vaporizer market has grown from $1.1Bil to $1.5Bil. It’s no secret the two industries are heading in complete opposite directions. Big tobacco did it before when Blu and Logics were acquired and we expect them to make the exact same move when it comes to the vapor industry. Finding the right ground-floor opportunity in a vapor industry leader now could pay monster dividends down the road. This is why we want you to begin researching Vaproin, Inc. (VAPOD) right now.

Read The Disclaimer Right Here & Right Now: **
#pennystock #pennyStocks #daytrading #daytrade #daytrader
 
home cleaning services princeton nj maid service atlanta prices

Posted at giovedì, 18 settembre 2014 18:57 Visit posters website
home recipe upholstery cleaner maid services in delhi ncr
 
Katie Newman

Posted at giovedì, 18 settembre 2014 18:57 Visit posters website
Vaporin Acquires "The Vape Store" With $2.6 Million in Annual Revenue



MIAMI, FL -- (Marketwired) -- 09/18/14 -- Vaporin, Inc. (OTCQB: VAPOD), a distributor and marketer of vaporizers, e-liquids products and electronic cigarettes, announced on 9-3-14 the closing of the acquisition of The Vape Store (** which operates four vape shops on the west coast of Florida with annualized revenue of approximately $2.6 million. This acquisition completes the fourth revenue stream in the Company's overall strategic business plan. The Company's existing online, convenience store and vending machine business model has already experienced sequential quarterly revenue growth of 130% in Vaporin's first five months of operations in 2014.


Chief Executive Officer Scott Frohman said, "The acquisition of this successful chain of vape stores will provide our management with the expertise and business model to quickly and efficiently complete a nationwide rollout of our own chain of vape stores in the very near future."



To complete the acquisition, The Company raised $880,000 from the sale of 8,000,000 shares of common stock at $0.11 per share in a private placement offering to four accredited investors. No broker-dealer was involved.



Mr. Frohman continued, "This acquisition will allow us to quickly participate in a high growth segment of the marketplace with very high margins, and profitability. Additionally, adding this fourth revenue stream is complementary to our existing three-pronged business model. The Vape Store chain brings an experienced and successful management team, established proprietary customer base and company owned distribution channel that includes retail store operations, an Internet sales channel, and additional wholesale business. This is yet another opportunity to strengthen our brand and expand our market share within the estimated $2.5 billion vaporizer industry that is projected to grow to $51 billion in 2030 by industry experts."



According to the Smoke-Free Alternatives Trade Association, an industry group, the estimated number of vape shops has more than tripled in the past year to 35,000. As thousands of vape shops have opened across the country where consumers can socialize while purchasing vaporizers along with an assortment of e-liquid flavors, sales growth has remained explosive. This acquisition provides Vaporin with the opportunity to continue to build its brand and enter this rapidly growing segment of the market. The Company also envisions making additional vape shop acquisitions.



Steve Cantrell, Founder of The Vape Store, commented, "We are very excited to join Vaporin which has done an excellent job of establishing its brand through c-store distribution and online marketing. We have similar business strategies and envision this transition to occur quickly and seamlessly. This platform will allow us to further expand our brick and mortar locations beyond the four we have established. I look forward to joining the team and assisting in this growth strategy."



About Vaporin, Inc.

Vaporin is a distributor and marketer of electronic cigarettes, vaporizers, and e-liquids products. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin is offered in a variety of disposable and rechargeable starter kits and flavors. The unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **



Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements including statements regarding future Vape Store acquisitions . The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the results of our marketing efforts including our online initiative, competition from other e-cig. companies and the major tobacco companies, our ability to efficiently and productively integrate the acquisition, our future stock price and cash resources, and new regulations which affect the distribution of these products. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



All of the securities were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 (the "Act") and Rule 506 promulgated thereunder. These securities may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements under the Act. The investors are accredited investors and there was no general solicitation.



Company Contact:

Vaporin, Inc.

Scott Frohman

Chief Executive Officer

305.842.2813

Email Contact



Investor Relations Contact:

Capital Markets Group, LLC

Valter Pinto

PH: (914) 669-0222 x201

or

(212) 398-3486

Email Contact



Source: Vaporin, Inc.



Released September 3, 2014
 
Katie Newman

Posted at giovedì, 18 settembre 2014 18:39 Visit posters website
Vaporin Acquires "The Vape Store" With $2.6 Million in Annual Revenue



MIAMI, FL -- (Marketwired) -- 09/18/14 -- Vaporin, Inc. (OTCQB: VAPOD), a distributor and marketer of vaporizers, e-liquids products and electronic cigarettes, announced on 9-3-14 the closing of the acquisition of The Vape Store (** which operates four vape shops on the west coast of Florida with annualized revenue of approximately $2.6 million. This acquisition completes the fourth revenue stream in the Company's overall strategic business plan. The Company's existing online, convenience store and vending machine business model has already experienced sequential quarterly revenue growth of 130% in Vaporin's first five months of operations in 2014.


Chief Executive Officer Scott Frohman said, "The acquisition of this successful chain of vape stores will provide our management with the expertise and business model to quickly and efficiently complete a nationwide rollout of our own chain of vape stores in the very near future."



To complete the acquisition, The Company raised $880,000 from the sale of 8,000,000 shares of common stock at $0.11 per share in a private placement offering to four accredited investors. No broker-dealer was involved.



Mr. Frohman continued, "This acquisition will allow us to quickly participate in a high growth segment of the marketplace with very high margins, and profitability. Additionally, adding this fourth revenue stream is complementary to our existing three-pronged business model. The Vape Store chain brings an experienced and successful management team, established proprietary customer base and company owned distribution channel that includes retail store operations, an Internet sales channel, and additional wholesale business. This is yet another opportunity to strengthen our brand and expand our market share within the estimated $2.5 billion vaporizer industry that is projected to grow to $51 billion in 2030 by industry experts."



According to the Smoke-Free Alternatives Trade Association, an industry group, the estimated number of vape shops has more than tripled in the past year to 35,000. As thousands of vape shops have opened across the country where consumers can socialize while purchasing vaporizers along with an assortment of e-liquid flavors, sales growth has remained explosive. This acquisition provides Vaporin with the opportunity to continue to build its brand and enter this rapidly growing segment of the market. The Company also envisions making additional vape shop acquisitions.



Steve Cantrell, Founder of The Vape Store, commented, "We are very excited to join Vaporin which has done an excellent job of establishing its brand through c-store distribution and online marketing. We have similar business strategies and envision this transition to occur quickly and seamlessly. This platform will allow us to further expand our brick and mortar locations beyond the four we have established. I look forward to joining the team and assisting in this growth strategy."



About Vaporin, Inc.

Vaporin is a distributor and marketer of electronic cigarettes, vaporizers, and e-liquids products. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin is offered in a variety of disposable and rechargeable starter kits and flavors. The unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **



Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements including statements regarding future Vape Store acquisitions . The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the results of our marketing efforts including our online initiative, competition from other e-cig. companies and the major tobacco companies, our ability to efficiently and productively integrate the acquisition, our future stock price and cash resources, and new regulations which affect the distribution of these products. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



All of the securities were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 (the "Act") and Rule 506 promulgated thereunder. These securities may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements under the Act. The investors are accredited investors and there was no general solicitation.



Company Contact:

Vaporin, Inc.

Scott Frohman

Chief Executive Officer

305.842.2813

Email Contact



Investor Relations Contact:

Capital Markets Group, LLC

Valter Pinto

PH: (914) 669-0222 x201

or

(212) 398-3486

Email Contact



Source: Vaporin, Inc.



Released September 3, 2014
 
iespēju dikana dieta

Posted at giovedì, 18 settembre 2014 16:50 Visit posters website
minūtes dikana dieta
 
tiem dikana dieta

Posted at giovedì, 18 settembre 2014 13:14 Visit posters website
iespējas dikana dieta
 
katie Newman

Posted at giovedì, 11 settembre 2014 15:10 Visit posters website
Vapor Group, Inc. Engages Franchise Attorney, Harold L. Kestenbaum, PC, and Embarks on Franchising of its Brands
Accesswire

DAVIE, FL / ACCESSWIRE / September 11, 2014 / Vapor Group, Inc. (VPOR), (the "Company"), announced today that it has engaged Harold L. Kestenbaum, PC, East Meadows, New York, as its franchise attorney to represent the Company in the franchising of its brands. Mr. Kestenbaum has been engaged to prepare and/or review any and all required State of federal franchising agreements and disclosure documents in order for the Company to fulfill the regulatory requirements of the nationwide franchising of its brands.

CEO Dror Svorai said, "As I have said previously, we are about to begin the franchising of our "Total Vapor" store concept in the Northeast corridor, North Carolina, Washington D.C. , Texas and other places over time. Each of these geographical markets represents tremendous sales potential and we are excited by what franchising can mean to us long term. Mr. Kestenbaum is a recognized legal authority in the private sector on franchising, and we are delighted to be able to work with him."

About the Vapor Group

Vapor Group, Inc., ** is in the business of designing, developing, manufacturing and marketing high quality, vaporizers and e-cigarette brands which use state-of-the-art electronic technology and specially formulated, "Made in the USA" e-liquids, which may or may not contain nicotine. It offers a range of products with unique e-liquid flavors that is unmatched in our industry. Its products are marketed under the Vapor Group, Total Vapor, Vapor 123 and Vapor Products brands. It sells nationwide through distributors, wholesalers and directly to consumers through its own websites and direct response advertising.

All of its E-cigarettes consist of a long-life battery, a heating element, a cartridge filled with an "e-liquid" and an atomizer which when heated vaporizes the e-liquid. Because E-cigarettes are not "lit" like regular cigarettes, they don't create flame, smoke from burning, ash, tar, noxious fumes or leftover "cigarette butts". As a result, they may be used virtually anywhere.

Vapor Group is committed to providing E-cigarettes that are convenient and economical to use, safer and healthier than traditional smoking, and which provide a flavorful, enjoyable smoking experience.

Vapor Group, Inc. is managed by a highly experienced team of executives committed to responsible business policies and practices, including the marketing of our products only to those eighteen years of age or older, not making or avoiding claims about our product health benefits, and fulfilling the requirements of all applicable laws and regulations.

Safe Harbor Statement:

This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Certain statements set forth in this press release constitute "forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

CONTACT:

Vapor Group, Inc.
954-792-8450

SOURCE: Vapor Group, Inc.
 
katie Newman

Posted at giovedì, 11 settembre 2014 14:55 Visit posters website
Vapor Group, Inc. Engages Franchise Attorney, Harold L. Kestenbaum, PC, and Embarks on Franchising of its Brands
Accesswire

DAVIE, FL / ACCESSWIRE / September 11, 2014 / Vapor Group, Inc. (VPOR), (the "Company"), announced today that it has engaged Harold L. Kestenbaum, PC, East Meadows, New York, as its franchise attorney to represent the Company in the franchising of its brands. Mr. Kestenbaum has been engaged to prepare and/or review any and all required State of federal franchising agreements and disclosure documents in order for the Company to fulfill the regulatory requirements of the nationwide franchising of its brands.

CEO Dror Svorai said, "As I have said previously, we are about to begin the franchising of our "Total Vapor" store concept in the Northeast corridor, North Carolina, Washington D.C. , Texas and other places over time. Each of these geographical markets represents tremendous sales potential and we are excited by what franchising can mean to us long term. Mr. Kestenbaum is a recognized legal authority in the private sector on franchising, and we are delighted to be able to work with him."

About the Vapor Group

Vapor Group, Inc., ** is in the business of designing, developing, manufacturing and marketing high quality, vaporizers and e-cigarette brands which use state-of-the-art electronic technology and specially formulated, "Made in the USA" e-liquids, which may or may not contain nicotine. It offers a range of products with unique e-liquid flavors that is unmatched in our industry. Its products are marketed under the Vapor Group, Total Vapor, Vapor 123 and Vapor Products brands. It sells nationwide through distributors, wholesalers and directly to consumers through its own websites and direct response advertising.

All of its E-cigarettes consist of a long-life battery, a heating element, a cartridge filled with an "e-liquid" and an atomizer which when heated vaporizes the e-liquid. Because E-cigarettes are not "lit" like regular cigarettes, they don't create flame, smoke from burning, ash, tar, noxious fumes or leftover "cigarette butts". As a result, they may be used virtually anywhere.

Vapor Group is committed to providing E-cigarettes that are convenient and economical to use, safer and healthier than traditional smoking, and which provide a flavorful, enjoyable smoking experience.

Vapor Group, Inc. is managed by a highly experienced team of executives committed to responsible business policies and practices, including the marketing of our products only to those eighteen years of age or older, not making or avoiding claims about our product health benefits, and fulfilling the requirements of all applicable laws and regulations.

Safe Harbor Statement:

This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Certain statements set forth in this press release constitute "forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

CONTACT:

Vapor Group, Inc.
954-792-8450

SOURCE: Vapor Group, Inc.
 
katie Newman

Posted at mercoledì, 10 settembre 2014 15:58 Visit posters website
Vaporin, Inc. Announces 1:50 Reverse Stock Split
Marketwired Vaporin, Inc.

MIAMI, FL--(Marketwired - Sep 10, 2014) - Vaporin, Inc. (OTCQB: VAPO), a distributor and marketer of electronic cigarettes, vaporizers and e-liquids products, today announced a 1:50 reverse stock split effective at the opening of trading on September 10, 2014. The strategic move by management makes Vaporin, Inc. more attractive to institutional investors as CEO Scott Frohman is preparing for a non-deal road show to present in front of numerous brokerage firms, hedge funds, and money managers. The Company is confident in the long-term benefits of the reverse split.

CEO Scott Frohman said, "We believe the positives of the reverse split far outweigh any negatives. Not only are we more attractive to institutional investors but the new structure makes it much easier for us to complete strategic acquisitions, which we plan to aggressively pursue heading into Q4. The post-reverse share price will also allow us to complete financings with much larger investment banks."

Mr. Frohman continued, "It has also been a focus of ours to build a strong Board of Directors with extensive investment experience and related industry experience and this new structure will help us do just that."

The Company is focused on increasing shareholder equity by continuing to increase sales revenue and completing more acquisitions to add to the bottom line. The new reverse split structure will help Vaporin, Inc. continue to progress with their business plan.

About Vaporin, Inc.
Vaporin is a distributor and marketer of electronic cigarettes, vaporizers, e-liquids and e-hookah products. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin has a unique Vaporizer product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements including statements regarding our completing future acquisitions, completing future financings and building a strong board of directors. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the effectiveness of our advertising campaign, consumer reaction to our advertising campaign, new regulations which affect the distribution of our products, our ability to locate and consummate agreements with acquisition targets, our future stock price and our ability to attract independent directors with the appropriate mix of skills. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:

Company
Vaporin, Inc.
Scott Frohman
Chief Executive Officer
305.842.2813
Email Contact

Investor Relations
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 x201
or
(212) 398-3486
Email Contact
 
Katie Newman

Posted at mercoledì, 10 settembre 2014 15:40 Visit posters website
Vaporin, Inc. Announces 1:50 Reverse Stock Split
Marketwired Vaporin, Inc.

MIAMI, FL--(Marketwired - Sep 10, 2014) - Vaporin, Inc. (OTCQB: VAPO), a distributor and marketer of electronic cigarettes, vaporizers and e-liquids products, today announced a 1:50 reverse stock split effective at the opening of trading on September 10, 2014. The strategic move by management makes Vaporin, Inc. more attractive to institutional investors as CEO Scott Frohman is preparing for a non-deal road show to present in front of numerous brokerage firms, hedge funds, and money managers. The Company is confident in the long-term benefits of the reverse split.

CEO Scott Frohman said, "We believe the positives of the reverse split far outweigh any negatives. Not only are we more attractive to institutional investors but the new structure makes it much easier for us to complete strategic acquisitions, which we plan to aggressively pursue heading into Q4. The post-reverse share price will also allow us to complete financings with much larger investment banks."

Mr. Frohman continued, "It has also been a focus of ours to build a strong Board of Directors with extensive investment experience and related industry experience and this new structure will help us do just that."

The Company is focused on increasing shareholder equity by continuing to increase sales revenue and completing more acquisitions to add to the bottom line. The new reverse split structure will help Vaporin, Inc. continue to progress with their business plan.

About Vaporin, Inc.
Vaporin is a distributor and marketer of electronic cigarettes, vaporizers, e-liquids and e-hookah products. Vaporin's innovative technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, Vaporin has a unique Vaporizer product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, **

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements including statements regarding our completing future acquisitions, completing future financings and building a strong board of directors. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the effectiveness of our advertising campaign, consumer reaction to our advertising campaign, new regulations which affect the distribution of our products, our ability to locate and consummate agreements with acquisition targets, our future stock price and our ability to attract independent directors with the appropriate mix of skills. Further information on our risk factors is contained in our filings with the SEC, including the Form 10-K filed on March 27, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:

Company
Vaporin, Inc.
Scott Frohman
Chief Executive Officer
305.842.2813
Email Contact

Investor Relations
Capital Markets Group, LLC
Valter Pinto
PH: (914) 669-0222 x201
or
(212) 398-3486
Email Contact
 
Rodrick R

Posted at martedì, 09 settembre 2014 16:56
Vaporin to Present at the 2014 Aegis Capital Conference on September 11, 2014

http://yhoo.it/1nIZ4tF
 
Katie Newman

Posted at venerdì, 05 settembre 2014 17:28 Visit posters website
ActiveCare Provides Revenue Projections of Approximately $11 Million for Next 12 Months

OREM, Utah-- ActiveCare Inc. (ACAR), a leader in diabetes monitoring and wellness services for self-insured employers nationwide, today provided a published report of revenue projections and a strategic business plan that details ActiveCare's vision for the next twelve months.

"We are pleased to provide revenue projections of approximately $11 million over the next twelve months as we have now secured signed contracts with over 100 corporate clients for our diabetes solution," stated David Derrick, CEO of ActiveCare. "We continue to expand our sales efforts into the northeast and southwest regions of the U.S. and expect to sign additional larger contracts throughout the remainder of the year. In the next 12 months we are forecasting to add 20,000 individuals on the ActiveCare diabetes solution. We are focused on attracting both large and small employers who are searching for ways to mitigate the growing costs of healthcare and improve the quality of that care. Our recent contracts combined with our growing sales pipelines have positioned us to achieve strong revenue growth in the coming year."

Highlights from Published Report:

ActiveCare is now servicing over 100 corporate clients.
Plans are in place to increase product offerings to include, products and services to monitor additional chronic illnesses.
ActiveCare has contracts with key partners who combined manage over 150,000 diabetic members. These partners are expected to implement our solutions to more of their diabetic population over the next 12 to 18 months.
ActiveCare has engaged Earl Hurst to assist the Company with building and deploying a national sales organization, as well as support the executive team with other business initiatives related to the Company. Earl has spent 29 years in executive sales and marketing positions with various health care companies. He previously served as Market President of Humana Utah and was an Executive Vice President of Fred A. Morton & Company, one of the largest health insurance brokers in the intermountain states.
For the full report please go to **

About ActiveCare

ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease. To learn more about ActiveCare, Inc., visit the website at **

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, regulatory uncertainty and economic pressure on the healthcare industry in particular, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with assimilating our recent acquisitions. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.


Contact:
Company Contact:
Bryan Dalton, Director of Market Strategies
ActiveCare, Inc.
(877) 862-5545
Investor Relations:
Capital Markets Group, LLC
(212) 398-3486

READ OUR FULL DISCLAIMER CLICK HERE (**
 
Katie Newman

Posted at venerdì, 05 settembre 2014 17:24 Visit posters website
ActiveCare Provides Revenue Projections of Approximately $11 Million for Next 12 Months

OREM, Utah-- ActiveCare Inc. (ACAR), a leader in diabetes monitoring and wellness services for self-insured employers nationwide, today provided a published report of revenue projections and a strategic business plan that details ActiveCare's vision for the next twelve months.

"We are pleased to provide revenue projections of approximately $11 million over the next twelve months as we have now secured signed contracts with over 100 corporate clients for our diabetes solution," stated David Derrick, CEO of ActiveCare. "We continue to expand our sales efforts into the northeast and southwest regions of the U.S. and expect to sign additional larger contracts throughout the remainder of the year. In the next 12 months we are forecasting to add 20,000 individuals on the ActiveCare diabetes solution. We are focused on attracting both large and small employers who are searching for ways to mitigate the growing costs of healthcare and improve the quality of that care. Our recent contracts combined with our growing sales pipelines have positioned us to achieve strong revenue growth in the coming year."

Highlights from Published Report:

ActiveCare is now servicing over 100 corporate clients.
Plans are in place to increase product offerings to include, products and services to monitor additional chronic illnesses.
ActiveCare has contracts with key partners who combined manage over 150,000 diabetic members. These partners are expected to implement our solutions to more of their diabetic population over the next 12 to 18 months.
ActiveCare has engaged Earl Hurst to assist the Company with building and deploying a national sales organization, as well as support the executive team with other business initiatives related to the Company. Earl has spent 29 years in executive sales and marketing positions with various health care companies. He previously served as Market President of Humana Utah and was an Executive Vice President of Fred A. Morton & Company, one of the largest health insurance brokers in the intermountain states.
For the full report please go to **

About ActiveCare

ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease. To learn more about ActiveCare, Inc., visit the website at **

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, regulatory uncertainty and economic pressure on the healthcare industry in particular, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with assimilating our recent acquisitions. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.


Contact:
Company Contact:
Bryan Dalton, Director of Market Strategies
ActiveCare, Inc.
(877) 862-5545
Investor Relations:
Capital Markets Group, LLC
(212) 398-3486

READ OUR FULL DISCLAIMER CLICK HERE (**
 
Katie Newman

Posted at venerdì, 05 settembre 2014 16:25 Visit posters website
________________________________________
Overview
ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease.
"ActiveCare is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. Based on projections, this should equate to nearly $2 million in net profit for ActiveCare."
________________________________________
Investment Highlights
• Right Market, Right Time. Diabetes is running rampant globally with the International Diabetes Federation projecting that there will be 552 million diabetics by 2030 if “urgent action” is not taken immediately. The American Diabetes Association estimates that U.S. diabetes costs soared 41 percent from $174 billion in 2007 to $245 billion in 2012.
• Patented Process. ActiveCare has developed and patented a proprietary process to diabetes management that includes diabetic products (state-of-the-art cellular glucometer and test supplies), data analytics and monitoring, and a 24/7/365 call center for monitoring of data and providing support around the clock, resulting in documented improved clinical outcomes and an overall reduction in the cost of care.
• Proven Savings. The January 2014 edition of US Endocrinology published data from a peer-reviewed, ActiveCare-sponsored study that concluded the company’s system saved an average of $3,384 annually for each patient as compared to subjects in the control group that were not utilizing the ActiveCare system.
• Growing Enrollment. In September, 2013, there were 2,500 patients enrolled in the ActiveCare diabetes management program. That figure has increased to more than 7,700 through July this year.
• Guidance for Continued Growth. ActiveCare is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. Based on projections, this should equate to nearly $2 million in net profit for ActiveCare.
• Major Partners. ActiveCare has partnerships with disease management company AHDI and pharmacy benefits manager Rx Benefits, two companies with an aggregate 160,000 diabetics under their umbrella.
________________________________________
Profile
Diabetes is often described as the silent killer, and for good reason. Many people never see the onset coming and the disease knows no bounds with regards to race, age or color. Nor does anyone know what causes diabetes. The myth believed by many is that diabetes is not a leading killer, but nothing is further from the truth. The American Diabetes Association reports that diabetes is the primary cause of death for 71,382 Americans annually and a contributor in another 160,022 deaths each year. Taking a more granular look at diabetes shows that it is a serious and potentially deadly disease with a list of co-morbidites that kills more people annually than breast cancer and AIDS combined. A hard fact is that two out of three people with diabetes die from heart disease or stoke, so while the cause of death may not actually be “diabetes;” it was the diabetes that greatly increased the risk of co-morbidities that resulted in the death knell.

Diabetes is arguably the world’s most challenging chronic disease with only isolated success in drug development to treat the disease. The number of people suffering from diabetes is simply staggering. The International Diabetes Federation estimates that 366 million people worldwide had diabetes in 2011. The IDF projects that number will rise to 552 million by 2030 if “urgent action” is not taken immediately to slow the diagnosis rate. Dialing it in to just the United States, the 2014 National Diabetes Statistics Report showed that 9.3 percent of the population, or 29.1 million Americans, had diabetes in 2012. The Centers for Disease Control and Prevention forecasts that 1 in 3 Americans will have diabetes by 2050 if the current trend continues.

These exorbitant numbers translate to tremendous costs associated with diabetes. The IDF said that in 2010 diabetes cost the global economy $376 billion, or nearly 12 percent of the world’s aggregate healthcare spending. In the U.S., the cost of diabetes has everyone looking for solutions. The American Diabetes Association estimates that diabetes costs soared 41 percent from $174 billion in 2007 to $245 billion in 2012. Dissecting the data shows $176 billion of the $245 billion in 2012 was direct costs of diabetes and the other $69 billion attributed to indirect costs, such as lost productivity.

There are three basic types of diabetes: gestational, Type 1 and Type 2. Gestational develops during pregnancy, causing high blood glucose (sugar) in a woman who did not have diabetes. This form typically disappears, but the woman is left at higher risk for Type 2 diabetes and cardiovascular disease later in life. People classified as Type 1 diabetics are often diagnosed during childhood or in their 20’s, which is why it was previously called juvenile diabetes. In theses cases, the patient’s body makes little to no insulin, a hormone necessary to convert sugar, starches and other food into energy for the body. Making up about 5 percent of total diabetes population, these patients are required to take daily insulin injections.

Type 2 diabetes is far and away the most prominent form of the disease, accounting for 90% to 95% of all diagnoses. For Type 2 diabetics, either the pancreas doesn’t produce enough insulin to keep blood glucose at normal levels or the body doesn’t properly process the insulin that is produced. The onset of Type 2 diabetes most usually comes on during adulthood, but poor diets and mushrooming obesity rates have been cited in increasing prevalence of diabetes diagnosis in children. These patients are not dependent on insulin injections and often take the medication metformin (or any number of biosimilar generics).

In any case, the body’s inability to properly control sugar levels results in glucose not penetrating cells as it should and leads to buildup in the blood. Without the glucose, cells don’t function correctly. Over time, the glucose accumulation in the blood can damage nerves and blood vessels, leading to eye, kidney and heart disease, as well as promote hardening of the arteries, called atherosclerosis, which is the culprit in strokes and heart attacks. Diabetic comas are also a possibility.

One of the biggest problems with controlling diabetes (if not the biggest problem) is patient compliance to a physician care plan, whether it’s medications, diet, exercise, blood glucose testing, etc. It is estimated that fewer than 30 percent of diabetics monitor their blood glucose levels on a regular basis. Remote care technologies offer significant promise and have been shown in several clinical trials to help reduce A1c levels, the gold standard of measuring blood sugar levels over extended periods of time.

A leader in this space is ActiveCare, Inc. (OTCQB:ACAR), a provider of a quality solution to diabetes management that includes diabetic products (state-of-the-art cellular glucometer and test supplies), data analytics and monitoring, resulting in documented improved clinical outcomes and an overall reduction in the cost of care.

ActiveCare has developed and patented a proprietary process and system that allows the company to assist its members in real-time, including a 24/7/365 call center for monitoring of data and providing support around the clock. By continuously monitoring of data, a patient, physician or caregiver can be alerted immediately of readings out of a range or at a dangerous level. This immediate intervention not only helps with taking corrective action, but also provides a “personal touch” that lets the patient know that they are not alone. Another element that the ActiveCare solution provides is documentation of progress of individuals or populations over time. In the form of regular reports, members, employers, disease management providers and channel partners are provided relevant data detailing the progress of any group or sub-group in the ActiveCare program. This documentation reflects not only clinical trends, but for select clients the ability to track the effect of the program on the individual or group’s cost of care.

The “proof is in the pudding,” as the old adage goes, with ActiveCare proving that their system saves payers money by better managing diabetes patients. The January 2014 edition of US Endocrinology published data from a peer-reviewed, ActiveCare-sponsored study that concluded the company’s system saved an average of $3,384 annually for each patient as compared to subjects in the control group that were not utilizing the ActiveCare system. This is quite a significant savings considering the cost of treating a diabetes patient runs about $13,700 per year.

The efficacy of this advanced monitoring system is translating to a growing membership at ActiveCare. In September, 2013, there were 2,500 patients enrolled. That figure has increased to more than 7,700 through July this year. ActiveCare calculates that each member generates $1,100 in recurring revenue. Less cost of sales, overhead and taxes, net income per active member is $192. At current membership levels, that’s $8.47 million in revenue and $1.48 million in net profit. Given that membership grew by more than 1,200 in July, it should not be surprising that the company is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. In a press release on August 25, ActiveCare CEO David Derrick said that the company has now secured signed contracts with over 100 corporate clients. The company has partnerships with disease management company AHDI and pharmacy benefits manager Rx Benefits, two companies with an aggregate 160,000 diabetics under their umbrella.

Even at the conservative estimate of $11 million in revenue, extrapolation of the figures should mean about $1.92 million in net profit for ActiveCare. ActiveCare currently has a market capitalization of $18.36 million (with shares at 40 cents each), converting to a price-to-earnings ration of roughly 9.5:1. This is a low P/E ratio for the industry. For example, Medtronic (NYSE:MDT) trades at a P/E ratio of 21:1. Boston Scientific (NYSE:BSX) trades at 46:1. That’s not implying that ActiveCare is in the same class with the multi-billion-dollar blue chips, but it does lend credence to the low P/E ratio if ActiveCare meets its projections.

The management team guiding ActiveCare is flush with experience and success. Former economics professor at the University of Utah and serial entrepreneur David Derrick (CEO, Chairman) has created several high tech Utah-based public companies that have received numerous patents, developed smart computerized home technologies, medical and health technologies and electronic monitoring GPS systems for elder safety and public protection. Michael Zane Jones serves at Chief Operations Officer at ActiveCare. He has been a founder and executive in several of the technology industry’s fastest growing companies, including servings as EVP of Sales and Marketing at iBahn (formerly STSN) while the company was recognized in consecutive years by Deloitte & Touche and Inc. Magazine for its explosive growth, expanding from $29 million to over $120 million in sales in a three-year period. Michael also founded Interactive Care in 2007 and filed several patents in the field of video collaboration as a tool for delivery of medical care. Earl Hurst has been brought on as President. Mr. Hurst, the former Market President for Humana (NYSE:HUM), has about three decades of sales, operations and management experience with start- up, private and publicly held health care related companies. This is just a sampling of the leadership at the helm of ActiveCare, with the rest of the team running the gamut of public and private companies, the healthcare sector and technology industry.

ActiveCare has a succinct business model in place that it is following to further deploy its patient monitoring solution across the country. The diabetes space is such a robust industry that only a small market penetration is necessary to generate tremendous sales. In a summary of revenue projections going forward, the company shows that garnering only 0.3% of the overall market, or 87,000 members (43,500 active members) will translate to $47.85 million in annualized member revenue. At a higher level of 3% of the market, or 870,000 members (435,000 active members), annualized member revenue would be $478.5 million.

Another interesting component of the industry is that the Centers for Medicare and Medicaid has a proposal on the table to begin reimbursing for remote technology for the first time in history starting at the first of January 2015. There are stipulations in the reimbursement requirements – such as the patient must be suffering from two or more chronic conditions and 20 minutes of time must be documented for each patient – that will take a closer look to see if ActiveCare will meet the criteria, but the point is that remote technology is at a tipping point to go mainstream. Increased market awareness and reimbursement policies will further amplify ActiveCare’s offerings and should lead to acceleration of the business plan.

Investors should clearly see the tremendous market opportunity at hand with diabetes. It represents an area of great unmet medical need on a global scale. Remote care technologies are starting to come under a vary favorable light given the collection of clinical data that shows it improves clinical outcomes for patients, which lessens the financial strain on already overburdened healthcare systems. Simply, what ActiveCare has developed and patented is a very logical answer to an enormous problem. It gives patients everything that they need to properly test their blood glucose and then monitors them to ensure that they are testing and maintaining proper protocol and blood sugar readings to help improve their quality of life and productivity. In turn, this saves providers money in both the near and long-term. We are at the start of the new age of healthcare and ActiveCare has assumed a leading position in the diabetes space. For even more information on the Company, a new company report was recently prepared and is available to view: Click here for report.
________________________________________
Management
David Derrick - Chief Executive Officer and Chairman of the Board

David Derrick, a former business Professor, a successful entrepreneur and social philanthropist has a Masters Degree in Business Administration from the University of Utah. Soon after graduation David started a real estate development business at the same time he was teaching economics and finance at the University of Utah. After four years on a dual track of business and teaching, David decided to focus primarily on business. David tackled business with the same zeal and dedication he demonstrated in former interests, becoming a consummate entrepreneur. Developing new and innovative technologies, he created several high tech Utah- based public companies which have received numerous international patents. In business Dave has developed smart computerized home technologies, medical and health technologies, and most recently, industry leading electronic monitoring GPS systems and services for elder safety and public protection.

Earl Hurst - Sales & Marketing Strategist

Earl is a C-Level Health Care Executive with over 29 years of sales and operations management experience with start- up, private and publically held health care related companies. He has demonstrated skills in developing and implementing business development strategies that optimize growth and improve financial performance. He is an effective communicator with cross-functional team leadership skills and has a passion for team building that creates a collaborative culture.

Earl has a comprehensive understanding of the health care landscape. Throughout his career he has worked with companies on a variety of sides of the health care delivery system. Before joining ActiveCare Earl was the Executive Vice President of Moreton & Company. Moreton is a brokerage and consulting firm specializing in health benefits and property & casualty insurance placement. In his role at Moreton he leads business development, client retention and community relations. Moreton employs 185 employees mainly throughout the intermountain region.

Prior to Moreton & Company, Earl served as Market President for Humana. Humana is a Fourtune 50 Company specializing in both commercial and Medicare health insurance. Earl opened up the Utah market for Humana helping to establishing them as a key competitor in the Utah Market.
Earl has served in various key Executive Sales roles with Pharmacy Benefit Management, Hosptialist, Hospice, Third-Party Administrators, Radiology Management Companies throughout his career. This experience provides Earl with a unique perspective of the challenges associated with our health care delivery system.

Earl received his Bachelor of Arts degree from Brigham Young University in 1984. He has been married to his wife Sandy for 33 years. They are the proud parents of 5 children and 2 grandchildren. Earl has been active in the community serving on a variety of non-profit boards including The Make A Wish Foundation, Hale Centre Theatre, Economic Development Corporation of Utah, Salt Lake City Chamber Board of Governors, and the Sandy City Chamber to name a few.

Michael Jones - Chief Operations Officer

Michael has been a founder and executive in several of the technology industry’s fastest growing companies. Mr. Jones founded Interactive Care in 2007, filing several patents in the field of video collaboration as a tool for delivery of medical care. As Executive Vice President at RemedyMD, Michael led in the advancement of medical collaboration and the utilization of informatics technologies for the treatment of obesity and diabetes. While Executive Vice President of Sales and Marketing at iBahn (formerly STSN), the company was recognized in consecutive years by Deloitte & Touche and Inc. Magazine for its explosive growth, expanding from $29M to over $120M in annual sales over a three-year period. Prior to iBahn, Mr. Jones led numerous sales and operations organizations at Iomega Corporation during a period of unprecedented growth, exponentially expanding its distribution, customer support, production and logistics capacities. Michael has also led in domestic and international senior sales leadership roles at Siebel Systems, Silicon Graphics and Oracle. A published author and contributor to periodicals and industry publications, Michael graduated from the University of Utah with a degree in English.

Marc Bratsman - Chief Financial Officer

Marc brings over a decade of corporate accounting and SEC experience. Prior to joining ActiveCare Marc served as the Chief Financial Officer of Steinway Management. At Steinway, Marc developed the financial reporting policies and procedures for corporate, fulfillment, customer service, and multiple niche eCommerce divisions. He also 
led a team tasked with improving our largest expense, online advertising on Google, Bing, Yahoo and re-marketing. The team successfully reduced the cost per sale on our largest websites. During this time he became a certified Google Adwords analyst and BingAds analyst. Prior to Steinway, Marc was a senior audit manager with Grant Thornton with serving both public and private companies in the retail, distribution, manufacturing, technology and benefit plan industries. My clients included Recreational Equipment Inc. (REI), Todd Shipyards (TOD), Telanetix (TNXI), Distant Lands Coffee Co., K&L Distributors, SafeWorks, Celebrate Express (BDAY), Cost-U-Less (CULS), LeMond Fitness, Zones (ZONS), Bensussen Deutsch & Associates, Professional Bowlers Association (the PBA), Bungie 401k, and the Starbucks 401k and ESPP.

Jonathan Olson - Chief Technology Officer

Mr. Olson has nearly 20 years of experience in managing the development and implementation of clinical informatics applications. As the first employee of TheraDoc, he led the architecture, design, and implementation of the TheraDoc Clinical Intelligence Platform. He has been a contributing author in numerous peer-reviewed publications and holds two patents. Olson played a key role during the acquisition of TheraDoc by Hospira, Inc. in 2009. During his tenure at Hospira TheraDoc, he also held positions of responsibility over the services organization, including project management, training, data integration and support. He was instrumental in helping the organization achieve Best in KLAS in 2012 for the Infection Control Assistant.

Prior to TheraDoc, Jonathan led the Web team at the University of Utah Health Sciences Center and was involved in the creation of one of the first web-based medical record systems in the world. Jonathan received his bachelor’s degree in computer science and further training in medical informatics from the University of Utah.

Darrell G. Meador - President, ActiveCare Biometrics

As a contributing founder of 4G (ActiveCare Biometrics), Mr. Meador has spent the last 15 years involved in healthcare technology and new business initiatives. Recently, Mr. Meador was the Vice-President of Marketing and Sales for VRI, a leader in the healthcare monitoring industry. Mr. Meador was hired to start and build the Telehealth business segment of the VRI business. After a successful launch and securing three contracts, Mr. Meador left to start 4G Biometrics. From 2003 to 2008 Mr. Meador served as the President, Texas Region of Informed Care, an innovative managed care organization that focus on Chronic Diabetics with annual revenue of over $20 million. From 2001 to 2003 he was the Founder/President of Digital Solutions for Medicine, Inc. a start-up consulting firm specializing in technology, management and education for healthcare and related companies. From 1994 to 2001 he was the Co-Founder/President of Reliance Training Networks, a provider of distance learning and communication services to the healthcare industry.

Today, Mr. Meador brings to 4G an intrinsic knowledge of the healthcare industry, new business development and relationships from his many successful ventures. He has established a multimillion-dollar technology, management and education company that realized Net Revenue of $15 million with a 55% net profit margin within 30 months of launch. He directed initiatives that led to the building and installation of the first privately owned digital satellite network that reached over 2,500 healthcare facilities nationwide. He has been honored with two “Excellence” awards and was acknowledged as the driving force behind a company distinguished as one of the fastest growing companies by the Pittsburgh High Tech Council.

Mr. Meador received his BA Degree from the University of North Texas in 1986. He also was an Academic All-American at Panola Junior College while on a Baseball scholarship.
________________________________________
Contact:
1365 West Business Park Drive
Orem, Utah 84058

Phone: 877-219-6050
Fax: 855-291-6384
E-mail: info@activecare.com
READ OUR FULL DISCLAIMER CLICK HERE (**
 
Katie Newman

Posted at venerdì, 05 settembre 2014 15:45 Visit posters website
________________________________________
Overview
ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease.
"ActiveCare is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. Based on projections, this should equate to nearly $2 million in net profit for ActiveCare."
________________________________________
Investment Highlights
• Right Market, Right Time. Diabetes is running rampant globally with the International Diabetes Federation projecting that there will be 552 million diabetics by 2030 if “urgent action” is not taken immediately. The American Diabetes Association estimates that U.S. diabetes costs soared 41 percent from $174 billion in 2007 to $245 billion in 2012.
• Patented Process. ActiveCare has developed and patented a proprietary process to diabetes management that includes diabetic products (state-of-the-art cellular glucometer and test supplies), data analytics and monitoring, and a 24/7/365 call center for monitoring of data and providing support around the clock, resulting in documented improved clinical outcomes and an overall reduction in the cost of care.
• Proven Savings. The January 2014 edition of US Endocrinology published data from a peer-reviewed, ActiveCare-sponsored study that concluded the company’s system saved an average of $3,384 annually for each patient as compared to subjects in the control group that were not utilizing the ActiveCare system.
• Growing Enrollment. In September, 2013, there were 2,500 patients enrolled in the ActiveCare diabetes management program. That figure has increased to more than 7,700 through July this year.
• Guidance for Continued Growth. ActiveCare is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. Based on projections, this should equate to nearly $2 million in net profit for ActiveCare.
• Major Partners. ActiveCare has partnerships with disease management company AHDI and pharmacy benefits manager Rx Benefits, two companies with an aggregate 160,000 diabetics under their umbrella.
________________________________________
Profile
Diabetes is often described as the silent killer, and for good reason. Many people never see the onset coming and the disease knows no bounds with regards to race, age or color. Nor does anyone know what causes diabetes. The myth believed by many is that diabetes is not a leading killer, but nothing is further from the truth. The American Diabetes Association reports that diabetes is the primary cause of death for 71,382 Americans annually and a contributor in another 160,022 deaths each year. Taking a more granular look at diabetes shows that it is a serious and potentially deadly disease with a list of co-morbidites that kills more people annually than breast cancer and AIDS combined. A hard fact is that two out of three people with diabetes die from heart disease or stoke, so while the cause of death may not actually be “diabetes;” it was the diabetes that greatly increased the risk of co-morbidities that resulted in the death knell.

Diabetes is arguably the world’s most challenging chronic disease with only isolated success in drug development to treat the disease. The number of people suffering from diabetes is simply staggering. The International Diabetes Federation estimates that 366 million people worldwide had diabetes in 2011. The IDF projects that number will rise to 552 million by 2030 if “urgent action” is not taken immediately to slow the diagnosis rate. Dialing it in to just the United States, the 2014 National Diabetes Statistics Report showed that 9.3 percent of the population, or 29.1 million Americans, had diabetes in 2012. The Centers for Disease Control and Prevention forecasts that 1 in 3 Americans will have diabetes by 2050 if the current trend continues.

These exorbitant numbers translate to tremendous costs associated with diabetes. The IDF said that in 2010 diabetes cost the global economy $376 billion, or nearly 12 percent of the world’s aggregate healthcare spending. In the U.S., the cost of diabetes has everyone looking for solutions. The American Diabetes Association estimates that diabetes costs soared 41 percent from $174 billion in 2007 to $245 billion in 2012. Dissecting the data shows $176 billion of the $245 billion in 2012 was direct costs of diabetes and the other $69 billion attributed to indirect costs, such as lost productivity.

There are three basic types of diabetes: gestational, Type 1 and Type 2. Gestational develops during pregnancy, causing high blood glucose (sugar) in a woman who did not have diabetes. This form typically disappears, but the woman is left at higher risk for Type 2 diabetes and cardiovascular disease later in life. People classified as Type 1 diabetics are often diagnosed during childhood or in their 20’s, which is why it was previously called juvenile diabetes. In theses cases, the patient’s body makes little to no insulin, a hormone necessary to convert sugar, starches and other food into energy for the body. Making up about 5 percent of total diabetes population, these patients are required to take daily insulin injections.

Type 2 diabetes is far and away the most prominent form of the disease, accounting for 90% to 95% of all diagnoses. For Type 2 diabetics, either the pancreas doesn’t produce enough insulin to keep blood glucose at normal levels or the body doesn’t properly process the insulin that is produced. The onset of Type 2 diabetes most usually comes on during adulthood, but poor diets and mushrooming obesity rates have been cited in increasing prevalence of diabetes diagnosis in children. These patients are not dependent on insulin injections and often take the medication metformin (or any number of biosimilar generics).

In any case, the body’s inability to properly control sugar levels results in glucose not penetrating cells as it should and leads to buildup in the blood. Without the glucose, cells don’t function correctly. Over time, the glucose accumulation in the blood can damage nerves and blood vessels, leading to eye, kidney and heart disease, as well as promote hardening of the arteries, called atherosclerosis, which is the culprit in strokes and heart attacks. Diabetic comas are also a possibility.

One of the biggest problems with controlling diabetes (if not the biggest problem) is patient compliance to a physician care plan, whether it’s medications, diet, exercise, blood glucose testing, etc. It is estimated that fewer than 30 percent of diabetics monitor their blood glucose levels on a regular basis. Remote care technologies offer significant promise and have been shown in several clinical trials to help reduce A1c levels, the gold standard of measuring blood sugar levels over extended periods of time.

A leader in this space is ActiveCare, Inc. (OTCQB:ACAR), a provider of a quality solution to diabetes management that includes diabetic products (state-of-the-art cellular glucometer and test supplies), data analytics and monitoring, resulting in documented improved clinical outcomes and an overall reduction in the cost of care.

ActiveCare has developed and patented a proprietary process and system that allows the company to assist its members in real-time, including a 24/7/365 call center for monitoring of data and providing support around the clock. By continuously monitoring of data, a patient, physician or caregiver can be alerted immediately of readings out of a range or at a dangerous level. This immediate intervention not only helps with taking corrective action, but also provides a “personal touch” that lets the patient know that they are not alone. Another element that the ActiveCare solution provides is documentation of progress of individuals or populations over time. In the form of regular reports, members, employers, disease management providers and channel partners are provided relevant data detailing the progress of any group or sub-group in the ActiveCare program. This documentation reflects not only clinical trends, but for select clients the ability to track the effect of the program on the individual or group’s cost of care.

The “proof is in the pudding,” as the old adage goes, with ActiveCare proving that their system saves payers money by better managing diabetes patients. The January 2014 edition of US Endocrinology published data from a peer-reviewed, ActiveCare-sponsored study that concluded the company’s system saved an average of $3,384 annually for each patient as compared to subjects in the control group that were not utilizing the ActiveCare system. This is quite a significant savings considering the cost of treating a diabetes patient runs about $13,700 per year.

The efficacy of this advanced monitoring system is translating to a growing membership at ActiveCare. In September, 2013, there were 2,500 patients enrolled. That figure has increased to more than 7,700 through July this year. ActiveCare calculates that each member generates $1,100 in recurring revenue. Less cost of sales, overhead and taxes, net income per active member is $192. At current membership levels, that’s $8.47 million in revenue and $1.48 million in net profit. Given that membership grew by more than 1,200 in July, it should not be surprising that the company is projecting revenue of approximately $11 million and the addition of 20,000 new members in the next 12 months. In a press release on August 25, ActiveCare CEO David Derrick said that the company has now secured signed contracts with over 100 corporate clients. The company has partnerships with disease management company AHDI and pharmacy benefits manager Rx Benefits, two companies with an aggregate 160,000 diabetics under their umbrella.

Even at the conservative estimate of $11 million in revenue, extrapolation of the figures should mean about $1.92 million in net profit for ActiveCare. ActiveCare currently has a market capitalization of $18.36 million (with shares at 40 cents each), converting to a price-to-earnings ration of roughly 9.5:1. This is a low P/E ratio for the industry. For example, Medtronic (NYSE:MDT) trades at a P/E ratio of 21:1. Boston Scientific (NYSE:BSX) trades at 46:1. That’s not implying that ActiveCare is in the same class with the multi-billion-dollar blue chips, but it does lend credence to the low P/E ratio if ActiveCare meets its projections.

The management team guiding ActiveCare is flush with experience and success. Former economics professor at the University of Utah and serial entrepreneur David Derrick (CEO, Chairman) has created several high tech Utah-based public companies that have received numerous patents, developed smart computerized home technologies, medical and health technologies and electronic monitoring GPS systems for elder safety and public protection. Michael Zane Jones serves at Chief Operations Officer at ActiveCare. He has been a founder and executive in several of the technology industry’s fastest growing companies, including servings as EVP of Sales and Marketing at iBahn (formerly STSN) while the company was recognized in consecutive years by Deloitte & Touche and Inc. Magazine for its explosive growth, expanding from $29 million to over $120 million in sales in a three-year period. Michael also founded Interactive Care in 2007 and filed several patents in the field of video collaboration as a tool for delivery of medical care. Earl Hurst has been brought on as President. Mr. Hurst, the former Market President for Humana (NYSE:HUM), has about three decades of sales, operations and management experience with start- up, private and publicly held health care related companies. This is just a sampling of the leadership at the helm of ActiveCare, with the rest of the team running the gamut of public and private companies, the healthcare sector and technology industry.

ActiveCare has a succinct business model in place that it is following to further deploy its patient monitoring solution across the country. The diabetes space is such a robust industry that only a small market penetration is necessary to generate tremendous sales. In a summary of revenue projections going forward, the company shows that garnering only 0.3% of the overall market, or 87,000 members (43,500 active members) will translate to $47.85 million in annualized member revenue. At a higher level of 3% of the market, or 870,000 members (435,000 active members), annualized member revenue would be $478.5 million.

Another interesting component of the industry is that the Centers for Medicare and Medicaid has a proposal on the table to begin reimbursing for remote technology for the first time in history starting at the first of January 2015. There are stipulations in the reimbursement requirements – such as the patient must be suffering from two or more chronic conditions and 20 minutes of time must be documented for each patient – that will take a closer look to see if ActiveCare will meet the criteria, but the point is that remote technology is at a tipping point to go mainstream. Increased market awareness and reimbursement policies will further amplify ActiveCare’s offerings and should lead to acceleration of the business plan.

Investors should clearly see the tremendous market opportunity at hand with diabetes. It represents an area of great unmet medical need on a global scale. Remote care technologies are starting to come under a vary favorable light given the collection of clinical data that shows it improves clinical outcomes for patients, which lessens the financial strain on already overburdened healthcare systems. Simply, what ActiveCare has developed and patented is a very logical answer to an enormous problem. It gives patients everything that they need to properly test their blood glucose and then monitors them to ensure that they are testing and maintaining proper protocol and blood sugar readings to help improve their quality of life and productivity. In turn, this saves providers money in both the near and long-term. We are at the start of the new age of healthcare and ActiveCare has assumed a leading position in the diabetes space. For even more information on the Company, a new company report was recently prepared and is available to view: Click here for report.
________________________________________
Management
David Derrick - Chief Executive Officer and Chairman of the Board

David Derrick, a former business Professor, a successful entrepreneur and social philanthropist has a Masters Degree in Business Administration from the University of Utah. Soon after graduation David started a real estate development business at the same time he was teaching economics and finance at the University of Utah. After four years on a dual track of business and teaching, David decided to focus primarily on business. David tackled business with the same zeal and dedication he demonstrated in former interests, becoming a consummate entrepreneur. Developing new and innovative technologies, he created several high tech Utah- based public companies which have received numerous international patents. In business Dave has developed smart computerized home technologies, medical and health technologies, and most recently, industry leading electronic monitoring GPS systems and services for elder safety and public protection.

Earl Hurst - Sales & Marketing Strategist

Earl is a C-Level Health Care Executive with over 29 years of sales and operations management experience with start- up, private and publically held health care related companies. He has demonstrated skills in developing and implementing business development strategies that optimize growth and improve financial performance. He is an effective communicator with cross-functional team leadership skills and has a passion for team building that creates a collaborative culture.

Earl has a comprehensive understanding of the health care landscape. Throughout his career he has worked with companies on a variety of sides of the health care delivery system. Before joining ActiveCare Earl was the Executive Vice President of Moreton & Company. Moreton is a brokerage and consulting firm specializing in health benefits and property & casualty insurance placement. In his role at Moreton he leads business development, client retention and community relations. Moreton employs 185 employees mainly throughout the intermountain region.

Prior to Moreton & Company, Earl served as Market President for Humana. Humana is a Fourtune 50 Company specializing in both commercial and Medicare health insurance. Earl opened up the Utah market for Humana helping to establishing them as a key competitor in the Utah Market.
Earl has served in various key Executive Sales roles with Pharmacy Benefit Management, Hosptialist, Hospice, Third-Party Administrators, Radiology Management Companies throughout his career. This experience provides Earl with a unique perspective of the challenges associated with our health care delivery system.

Earl received his Bachelor of Arts degree from Brigham Young University in 1984. He has been married to his wife Sandy for 33 years. They are the proud parents of 5 children and 2 grandchildren. Earl has been active in the community serving on a variety of non-profit boards including The Make A Wish Foundation, Hale Centre Theatre, Economic Development Corporation of Utah, Salt Lake City Chamber Board of Governors, and the Sandy City Chamber to name a few.

Michael Jones - Chief Operations Officer

Michael has been a founder and executive in several of the technology industry’s fastest growing companies. Mr. Jones founded Interactive Care in 2007, filing several patents in the field of video collaboration as a tool for delivery of medical care. As Executive Vice President at RemedyMD, Michael led in the advancement of medical collaboration and the utilization of informatics technologies for the treatment of obesity and diabetes. While Executive Vice President of Sales and Marketing at iBahn (formerly STSN), the company was recognized in consecutive years by Deloitte & Touche and Inc. Magazine for its explosive growth, expanding from $29M to over $120M in annual sales over a three-year period. Prior to iBahn, Mr. Jones led numerous sales and operations organizations at Iomega Corporation during a period of unprecedented growth, exponentially expanding its distribution, customer support, production and logistics capacities. Michael has also led in domestic and international senior sales leadership roles at Siebel Systems, Silicon Graphics and Oracle. A published author and contributor to periodicals and industry publications, Michael graduated from the University of Utah with a degree in English.

Marc Bratsman - Chief Financial Officer

Marc brings over a decade of corporate accounting and SEC experience. Prior to joining ActiveCare Marc served as the Chief Financial Officer of Steinway Management. At Steinway, Marc developed the financial reporting policies and procedures for corporate, fulfillment, customer service, and multiple niche eCommerce divisions. He also 
led a team tasked with improving our largest expense, online advertising on Google, Bing, Yahoo and re-marketing. The team successfully reduced the cost per sale on our largest websites. During this time he became a certified Google Adwords analyst and BingAds analyst. Prior to Steinway, Marc was a senior audit manager with Grant Thornton with serving both public and private companies in the retail, distribution, manufacturing, technology and benefit plan industries. My clients included Recreational Equipment Inc. (REI), Todd Shipyards (TOD), Telanetix (TNXI), Distant Lands Coffee Co., K&L Distributors, SafeWorks, Celebrate Express (BDAY), Cost-U-Less (CULS), LeMond Fitness, Zones (ZONS), Bensussen Deutsch & Associates, Professional Bowlers Association (the PBA), Bungie 401k, and the Starbucks 401k and ESPP.

Jonathan Olson - Chief Technology Officer

Mr. Olson has nearly 20 years of experience in managing the development and implementation of clinical informatics applications. As the first employee of TheraDoc, he led the architecture, design, and implementation of the TheraDoc Clinical Intelligence Platform. He has been a contributing author in numerous peer-reviewed publications and holds two patents. Olson played a key role during the acquisition of TheraDoc by Hospira, Inc. in 2009. During his tenure at Hospira TheraDoc, he also held positions of responsibility over the services organization, including project management, training, data integration and support. He was instrumental in helping the organization achieve Best in KLAS in 2012 for the Infection Control Assistant.

Prior to TheraDoc, Jonathan led the Web team at the University of Utah Health Sciences Center and was involved in the creation of one of the first web-based medical record systems in the world. Jonathan received his bachelor’s degree in computer science and further training in medical informatics from the University of Utah.

Darrell G. Meador - President, ActiveCare Biometrics

As a contributing founder of 4G (ActiveCare Biometrics), Mr. Meador has spent the last 15 years involved in healthcare technology and new business initiatives. Recently, Mr. Meador was the Vice-President of Marketing and Sales for VRI, a leader in the healthcare monitoring industry. Mr. Meador was hired to start and build the Telehealth business segment of the VRI business. After a successful launch and securing three contracts, Mr. Meador left to start 4G Biometrics. From 2003 to 2008 Mr. Meador served as the President, Texas Region of Informed Care, an innovative managed care organization that focus on Chronic Diabetics with annual revenue of over $20 million. From 2001 to 2003 he was the Founder/President of Digital Solutions for Medicine, Inc. a start-up consulting firm specializing in technology, management and education for healthcare and related companies. From 1994 to 2001 he was the Co-Founder/President of Reliance Training Networks, a provider of distance learning and communication services to the healthcare industry.

Today, Mr. Meador brings to 4G an intrinsic knowledge of the healthcare industry, new business development and relationships from his many successful ventures. He has established a multimillion-dollar technology, management and education company that realized Net Revenue of $15 million with a 55% net profit margin within 30 months of launch. He directed initiatives that led to the building and installation of the first privately owned digital satellite network that reached over 2,500 healthcare facilities nationwide. He has been honored with two “Excellence” awards and was acknowledged as the driving force behind a company distinguished as one of the fastest growing companies by the Pittsburgh High Tech Council.

Mr. Meador received his BA Degree from the University of North Texas in 1986. He also was an Academic All-American at Panola Junior College while on a Baseball scholarship.
________________________________________
Contact:
1365 West Business Park Drive
Orem, Utah 84058

Phone: 877-219-6050
Fax: 855-291-6384
E-mail: info@activecare.com
READ OUR FULL DISCLAIMER CLICK HERE (**
 
Katie Newman

Posted at giovedì, 04 settembre 2014 19:08 Visit posters website
ActiveCare Provides Membership Projections of 17,000 New Members by June 30, 2015

OREM, Utah, Sept. 4, 2014 -- ActiveCare Inc. (ACAR), a leader in diabetes monitoring and wellness services for self-insured employers nationwide, previously announced in a published report a projection to add 17,000 new members between October 1, 2014 and June 30, 2015. The Company had previously announced projections of 2,500 new members for the quarter ending September 30, 2014, which the Company expects to meet.

"We are pleased that our new plan of working with our channel partners is enabling us to meet our membership goals for our current quarter," commented David Derrick, Chairman and CEO of ActiveCare. "Our membership growth will allow us to achieve over $11 million in revenue in the next 12 months. Major contracts with key partners such as AHDI and RxBenefits continue to add new members on an ongoing basis as we work to implement our solutions to a greater portion of their diabetic population."

This growth comes as ActiveCare is expanding its sales and marketing resources and has hired additional sales executives over the past three months. The Company is focusing on regional areas where the sales team has improved market intelligence and understanding for better market penetration.

"Our market continues to grow as it is now estimated that by the end of year there will be over 29 million people in the U.S. will be diagnosed with Type 2 Diabetes. The cost to the healthcare system is approximately $400 billion annually. Our new sales plan is expected to meet our growth expectations as our monitoring solution lowers claims costs for individuals and healthcare providers," concluded Derrick.

To see the full ActiveCare Report please go to:

**

About ActiveCare

ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease. To learn more about ActiveCare, Inc., visit the website at **

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, regulatory uncertainty and economic pressure on the healthcare industry in particular, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with assimilating our recent acquisitions. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.


Contact:
Company Contact:
Bryan Dalton, Director of Market Strategies
ActiveCare, Inc.
(877) 862-5545
Investor Relations:
Capital Markets Group, LLC
(212) 398-3486
 
Katie Newman

Posted at giovedì, 04 settembre 2014 18:53 Visit posters website
ActiveCare Provides Membership Projections of 17,000 New Members by June 30, 2015

OREM, Utah, Sept. 4, 2014 -- ActiveCare Inc. (ACAR), a leader in diabetes monitoring and wellness services for self-insured employers nationwide, previously announced in a published report a projection to add 17,000 new members between October 1, 2014 and June 30, 2015. The Company had previously announced projections of 2,500 new members for the quarter ending September 30, 2014, which the Company expects to meet.

"We are pleased that our new plan of working with our channel partners is enabling us to meet our membership goals for our current quarter," commented David Derrick, Chairman and CEO of ActiveCare. "Our membership growth will allow us to achieve over $11 million in revenue in the next 12 months. Major contracts with key partners such as AHDI and RxBenefits continue to add new members on an ongoing basis as we work to implement our solutions to a greater portion of their diabetic population."

This growth comes as ActiveCare is expanding its sales and marketing resources and has hired additional sales executives over the past three months. The Company is focusing on regional areas where the sales team has improved market intelligence and understanding for better market penetration.

"Our market continues to grow as it is now estimated that by the end of year there will be over 29 million people in the U.S. will be diagnosed with Type 2 Diabetes. The cost to the healthcare system is approximately $400 billion annually. Our new sales plan is expected to meet our growth expectations as our monitoring solution lowers claims costs for individuals and healthcare providers," concluded Derrick.

To see the full ActiveCare Report please go to:

**

About ActiveCare

ActiveCare, Inc. provides patented diabetes monitoring and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. Headquartered in Orem, Utah and publicly traded on the OTC Bulletin Board under symbol ACAR, ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease. To learn more about ActiveCare, Inc., visit the website at **

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, regulatory uncertainty and economic pressure on the healthcare industry in particular, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with assimilating our recent acquisitions. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.


Contact:
Company Contact:
Bryan Dalton, Director of Market Strategies
ActiveCare, Inc.
(877) 862-5545
Investor Relations:
Capital Markets Group, LLC
(212) 398-3486
 
Babaran

Posted at giovedì, 21 agosto 2014 12:13 Visit posters website
Coming in now
 
Katie Newman

Posted at martedì, 19 agosto 2014 16:46 Visit posters website
Big Pharma And Medical Marijuana; How Can They Coexist?

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary

Companies like GW Pharmaceuticals has already established licensing with pharma companies abroad.
There still has yet to be a mass appeal for state side interest in the Life Sciences segment of medical marijuana.
GrowBLOX grow chamber recently arrived in Las Vegas allowing GBLX to officially cultivate a consistent medical grade product which could appeal in a similar way as GWPH.
There's opportunity for emerging companies to become acquisition or licensing targets for Big Pharma to come in within the near future as popular opinion shifts in support of alternative medicine.
Over the last few months, I've been closely following the marijuana industry. Anywhere from accessories to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.

GrowBLOX (OTCQB:GBLX) Sciences has been a focus of mine, first based on the company's expansion model through partnerships in several marijuana friendly states, as well as the actual technology that GBLX has created. The GrowBLOX cultivation chamber is specifically designed to produce optimal environmental growing conditions for medical cannabis cultivation, and is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal marijuana. Up until this point, investors and on-lookers have only been able to view this through computer renderings and images of an empty box, which has lead to much speculation as to the actual operation of the technology and, in turn, the company.

Since early July, the stock has pulled back to prices as low as $1 (a price it hasn't seen since May) based on what I feel are concerns over the company's actual operations. It is pre-revenue and to this point, has been kept afloat through financing activities. Though partnerships have been in place and the company has hit several milestones especially in Nevada, I can say that based on responses to my own articles on the company, investors are looking for something more tangible.

On August 11 GB Sciences officially announced that the first GrowBLOX cultivation chamber had arrived in Las Vegas, NV. Furthermore, the company had stated that it will be posting images of the GrowBLOX™ along with a webcam feed of the growth process inside the cultivation chamber on their corporate website.

"Having our cutting-edge GrowBLOX™ chamber here is very exciting because it represents one important step towards completing our vision of a complete, proprietary GrowBLOX™ Cultivation Solution…Our GrowBLOX™ Cultivation Solutions will allow us to consistently grow toxin-free medical marijuana of the highest efficacy from harvest to harvest."

-Chief Science Officer Andrea Small-Howard, PhD, MBA-

So far GBLX has embedded itself in several key markets with the first being Nevada followed by Florida and the latest state to open its doors, Illinois. With the quick expansion of the company's footprint, the time has come for GBLX to see the rubber meet the road so to speak.

Since announcing this latest company development, GBLX stock has traded sideways and consistently in a price channel between $1.16-$1.22 in a relatively liquid market. This brings rise to what would appear to be a new lower support level for GBLX given that there's been so much accumulation in this current channel. This may also be something to look into more closely being that the chamber arrival is only one of what should be more over the coming months. Once medical sales begin, GB Sciences could be posting good revenue numbers given the market opportunity.

(click to enlarge)


Take Nevada for instance. GrowBLOX was 1 of only 18 companies that were approved for special licensing and more importantly, the company's Fort Apache location is the only dispensary to service the needs of patients in that area, making the special use permit license all the more important for Clark County and for GBLX. In looking at the overall market within Nevada, it appears that medical operators have the potential to make a lot more on the sale of marijuana as compared to other states based on the taxes imposed; Nevada is at a mere 2%.

There've been many comments both positive and negative regarding the actual operation of the company and after the announcement on the arrival of the cultivation chamber, this gives rise to the company's ability to start growing proprietary strains to distribute to its dispensaries and partner dispensaries. For GBLX and the industry as a whole, the arrival of this first GrowBLOX chamber signals a new way for cannabis cultivation consistency.

In a recent video of GrowBLOX CFO, Steven Weldon, he's of the thought that through this new way of consistent medical marijuana cultivation, there will be a new standard set that could ultimately compete with Big Pharma. Mr. Weldon states that marijuana is not based so much on "getting high" but is based more on quality of life and making a medical product.

Comparatively speaking, look at a company like GW Pharmaceuticals (NASDAQ:GWPH), which has a product portfolio of cannabinoid prescription medicines to meet patient needs "in a wide range of therapeutic indications". GW trades on the Nasdaq and IPO'd at $8.90 in May 2013. The company states that it's focused on the Life Science space instead of the class of 'Medical Marijuana'. GW has entered into five separate licensing agreements for its Sativex product with Bayer HealthCare (a subsidiary of Bayer AG) in the UK and Canada; Almirall (ALM.ES) in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis AG (NYSE:NVS) in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.

In its Q3 filing, GW realized an increase in revenue to $13million, up 4% from the previous quarter. In addition to this, the company openly states that its shown a net loss on the books due to increased R&D. However, this R&D has lead to both phase 2 and phase 3 testing of the company's proprietary products for treatment of anything from cancer pain to epilepsy. Furthermore, over the course of the last 3 months, GWPH has increased in share price from lows of $63 in May to as high as $111.46 during the first week of July. Currently the stock sits around $93 a share following the turnover from the late June- early July rally.

When considering medical marijuana as more of a life science as opposed to a drug, there's obvious potential in the marketplace especially abroad as indicated by GW's progress with licensing to pharmaceutical companies outside of the US. While the nation continues to litigate the rollout of an effective policy for this new industry, companies like GrowBLOX and GW Pharma have identified a more viable approach to growth within the space. By being able to provide pharmaceutical grade products, the opportunity for licensing and partnerships becomes more evident as the much larger GWPH suggests. I would imagine that if there was a way to mass-produce strains of marijuana like Johnson and Johnson produces Tylenol and Bayer Produces aspirin, the industry as a whole could be in for a big change with the benefits being realized by patients in need.

It will be an interesting third quarter moving forward for GBLX because not only will the company be actively growing its proprietary strains but also other states will have an opportunity to vote on and potentially implement medical and recreational programs. I think for both GW Pharma and GB Sciences, the real opportunity will be the ability to produce a consistent, medical grade product that big pharma companies can either license or simply purchase at wholesale. If GWPH is any example of what an emerging company like GBLX can become, the future should be brighter as GrowBLOX continues to implement more R & D for medical-grade marijuana cultivation as well as proprietary cannabinoid extraction methodologies. Currently, under the scientific direction of Dr. Andrea Small-Howard, PhD, MBA, the company will be pursuing a "biphasic product pipeline strategy" involving a near-term accelerated development plan; as well as a longer-term commitment to build a traditional product development pipeline.

According to GB Sciences, the company will utilize its patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline. Once initiated, GBLX states that it will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company's investment. In the most recent quarterly filing GB states, "Our initial phase will be the accelerated "virtual pharma" and will include obtaining license patents on promising projects, testing and FDA approval, and co-developing the resulting product for marketing and sale. The next phase will involve setting up a traditional biopharmaceutical research method to allow out company to begin the R&D process in-house and fully own resulting patents and products."

In comparison to GW Pharma and what GB Sciences could become, the upside does not come without risk especially during the early stages that the company is in right now. Even though they have over $3million in cash, all of the company's operations have been backed by heavy financing activities and up until this point, there are zero revenues to report. In addition to this, GB also states in their Q that the company will require even more operating cash through 2015 to the tune of more than $4million.

Potential investment risks also include the overall market risk which is quite obvious when thinking about dilution. Despite the positive sentiment driven by outside institutional investors like Lazarus Partners, building a position from stock purchases directly through the market, I think investors should err on the side of caution when making their own investment decisions. Know that unlike GW Pharma, GBLX is in its development stage and even with the established partnerships in Nevada, Illinois, and Florida the company still needs to produce an actual product. Notwithstanding these risks, I think that the arrival of the actual chamber should be the first stepping stone to moving forward in producing revenues.

Finally, with the size of the marijuana industry set to grow by billions of dollars over the next 5 years, I'm sure that once there is an established market at the national level, we should start to see some of the smaller companies take an increased market share by the time industries like Big Pharma begin to actually enter the space.

Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
 
Katie Newman

Posted at martedì, 19 agosto 2014 16:30 Visit posters website
Big Pharma And Medical Marijuana; How Can They Coexist?

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary

Companies like GW Pharmaceuticals has already established licensing with pharma companies abroad.
There still has yet to be a mass appeal for state side interest in the Life Sciences segment of medical marijuana.
GrowBLOX grow chamber recently arrived in Las Vegas allowing GBLX to officially cultivate a consistent medical grade product which could appeal in a similar way as GWPH.
There's opportunity for emerging companies to become acquisition or licensing targets for Big Pharma to come in within the near future as popular opinion shifts in support of alternative medicine.
Over the last few months, I've been closely following the marijuana industry. Anywhere from accessories to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.

GrowBLOX (OTCQB:GBLX) Sciences has been a focus of mine, first based on the company's expansion model through partnerships in several marijuana friendly states, as well as the actual technology that GBLX has created. The GrowBLOX cultivation chamber is specifically designed to produce optimal environmental growing conditions for medical cannabis cultivation, and is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal marijuana. Up until this point, investors and on-lookers have only been able to view this through computer renderings and images of an empty box, which has lead to much speculation as to the actual operation of the technology and, in turn, the company.

Since early July, the stock has pulled back to prices as low as $1 (a price it hasn't seen since May) based on what I feel are concerns over the company's actual operations. It is pre-revenue and to this point, has been kept afloat through financing activities. Though partnerships have been in place and the company has hit several milestones especially in Nevada, I can say that based on responses to my own articles on the company, investors are looking for something more tangible.

On August 11 GB Sciences officially announced that the first GrowBLOX cultivation chamber had arrived in Las Vegas, NV. Furthermore, the company had stated that it will be posting images of the GrowBLOX™ along with a webcam feed of the growth process inside the cultivation chamber on their corporate website.

"Having our cutting-edge GrowBLOX™ chamber here is very exciting because it represents one important step towards completing our vision of a complete, proprietary GrowBLOX™ Cultivation Solution…Our GrowBLOX™ Cultivation Solutions will allow us to consistently grow toxin-free medical marijuana of the highest efficacy from harvest to harvest."

-Chief Science Officer Andrea Small-Howard, PhD, MBA-

So far GBLX has embedded itself in several key markets with the first being Nevada followed by Florida and the latest state to open its doors, Illinois. With the quick expansion of the company's footprint, the time has come for GBLX to see the rubber meet the road so to speak.

Since announcing this latest company development, GBLX stock has traded sideways and consistently in a price channel between $1.16-$1.22 in a relatively liquid market. This brings rise to what would appear to be a new lower support level for GBLX given that there's been so much accumulation in this current channel. This may also be something to look into more closely being that the chamber arrival is only one of what should be more over the coming months. Once medical sales begin, GB Sciences could be posting good revenue numbers given the market opportunity.

(click to enlarge)


Take Nevada for instance. GrowBLOX was 1 of only 18 companies that were approved for special licensing and more importantly, the company's Fort Apache location is the only dispensary to service the needs of patients in that area, making the special use permit license all the more important for Clark County and for GBLX. In looking at the overall market within Nevada, it appears that medical operators have the potential to make a lot more on the sale of marijuana as compared to other states based on the taxes imposed; Nevada is at a mere 2%.

There've been many comments both positive and negative regarding the actual operation of the company and after the announcement on the arrival of the cultivation chamber, this gives rise to the company's ability to start growing proprietary strains to distribute to its dispensaries and partner dispensaries. For GBLX and the industry as a whole, the arrival of this first GrowBLOX chamber signals a new way for cannabis cultivation consistency.

In a recent video of GrowBLOX CFO, Steven Weldon, he's of the thought that through this new way of consistent medical marijuana cultivation, there will be a new standard set that could ultimately compete with Big Pharma. Mr. Weldon states that marijuana is not based so much on "getting high" but is based more on quality of life and making a medical product.

Comparatively speaking, look at a company like GW Pharmaceuticals (NASDAQ:GWPH), which has a product portfolio of cannabinoid prescription medicines to meet patient needs "in a wide range of therapeutic indications". GW trades on the Nasdaq and IPO'd at $8.90 in May 2013. The company states that it's focused on the Life Science space instead of the class of 'Medical Marijuana'. GW has entered into five separate licensing agreements for its Sativex product with Bayer HealthCare (a subsidiary of Bayer AG) in the UK and Canada; Almirall (ALM.ES) in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis AG (NYSE:NVS) in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.

In its Q3 filing, GW realized an increase in revenue to $13million, up 4% from the previous quarter. In addition to this, the company openly states that its shown a net loss on the books due to increased R&D. However, this R&D has lead to both phase 2 and phase 3 testing of the company's proprietary products for treatment of anything from cancer pain to epilepsy. Furthermore, over the course of the last 3 months, GWPH has increased in share price from lows of $63 in May to as high as $111.46 during the first week of July. Currently the stock sits around $93 a share following the turnover from the late June- early July rally.

When considering medical marijuana as more of a life science as opposed to a drug, there's obvious potential in the marketplace especially abroad as indicated by GW's progress with licensing to pharmaceutical companies outside of the US. While the nation continues to litigate the rollout of an effective policy for this new industry, companies like GrowBLOX and GW Pharma have identified a more viable approach to growth within the space. By being able to provide pharmaceutical grade products, the opportunity for licensing and partnerships becomes more evident as the much larger GWPH suggests. I would imagine that if there was a way to mass-produce strains of marijuana like Johnson and Johnson produces Tylenol and Bayer Produces aspirin, the industry as a whole could be in for a big change with the benefits being realized by patients in need.

It will be an interesting third quarter moving forward for GBLX because not only will the company be actively growing its proprietary strains but also other states will have an opportunity to vote on and potentially implement medical and recreational programs. I think for both GW Pharma and GB Sciences, the real opportunity will be the ability to produce a consistent, medical grade product that big pharma companies can either license or simply purchase at wholesale. If GWPH is any example of what an emerging company like GBLX can become, the future should be brighter as GrowBLOX continues to implement more R & D for medical-grade marijuana cultivation as well as proprietary cannabinoid extraction methodologies. Currently, under the scientific direction of Dr. Andrea Small-Howard, PhD, MBA, the company will be pursuing a "biphasic product pipeline strategy" involving a near-term accelerated development plan; as well as a longer-term commitment to build a traditional product development pipeline.

According to GB Sciences, the company will utilize its patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline. Once initiated, GBLX states that it will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company's investment. In the most recent quarterly filing GB states, "Our initial phase will be the accelerated "virtual pharma" and will include obtaining license patents on promising projects, testing and FDA approval, and co-developing the resulting product for marketing and sale. The next phase will involve setting up a traditional biopharmaceutical research method to allow out company to begin the R&D process in-house and fully own resulting patents and products."

In comparison to GW Pharma and what GB Sciences could become, the upside does not come without risk especially during the early stages that the company is in right now. Even though they have over $3million in cash, all of the company's operations have been backed by heavy financing activities and up until this point, there are zero revenues to report. In addition to this, GB also states in their Q that the company will require even more operating cash through 2015 to the tune of more than $4million.

Potential investment risks also include the overall market risk which is quite obvious when thinking about dilution. Despite the positive sentiment driven by outside institutional investors like Lazarus Partners, building a position from stock purchases directly through the market, I think investors should err on the side of caution when making their own investment decisions. Know that unlike GW Pharma, GBLX is in its development stage and even with the established partnerships in Nevada, Illinois, and Florida the company still needs to produce an actual product. Notwithstanding these risks, I think that the arrival of the actual chamber should be the first stepping stone to moving forward in producing revenues.

Finally, with the size of the marijuana industry set to grow by billions of dollars over the next 5 years, I'm sure that once there is an established market at the national level, we should start to see some of the smaller companies take an increased market share by the time industries like Big Pharma begin to actually enter the space.

Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
 
thomson

Posted at martedì, 19 agosto 2014 05:24 Visit posters website
When it came time to Knowledge.
 
yamahot

Posted at giovedì, 14 agosto 2014 04:31 Visit posters website
Information of your site is useful and knowledgeable about most
 

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Slide Show Pict
Visitors: 2591468